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Abstract
In the last decade, primarily through the use of sequencing, much has been learned about the trillions of
microorganisms that reside in human hosts. These microorganisms play a wide range of roles including
helping our immune systems develop, digesting our food, and protecting us from the invasion of pathogenic
organisms. My thesis focuses on the characterization of fungal, viral, and bacterial communities in humans,
investigating the use of defined microbial communities to cure diseases in animal models, and examining the
effects of human microbiome modifications through fecal microbiota transfers. In the first part of this thesis, I
use deep sequencing of ribosomal RNA gene tags to characterize the composition of the bacterial, fungal, and
archaeal microbiota in pediatric patients with Inflammatory Bowel Disease and healthy controls. Archaeal
reads were rare in the pediatric samples, whereas an abundant amount of fungal reads was recovered. Pediatric
IBD was found to be associated with reduced diversity in both fungal and bacterial gut microbiota, and
specific Candida taxa were increased in abundance in the IBD samples. I, then, describe my use of a variety of
experimental and computational methods to study the viral communities of immune-compromised lung
transplant recipients. Anelloviruses, circular, single-stranded DNA viruses, were found in all lung samples but
were 56 times more abundant in samples from lung transplant recipients as compared to healthy controls or
HIV+ subjects. In the third part of this thesis, I describe the use of defined microbial communities in mice,
and its ability to reduce the production of ammonia long term and mitigate hepatic encephalopathy. This was
shown to be true in both mice on a normal protein diet or a low protein diet. Last, I investigate the transfer of
viral communities between humans through FMT and characterize features associated with efficient
transmission. A case series where feces from a single donor were used to treat three children with ulcerative
colitis was used for the analysis. Ultimately this work showed that multiple viral lineages do transfer between
human individuals through fecal microbiota transplants, but in this case series none of the viruses were known
to infect human cells. In this thesis, I elucidate numerous roles for the microbiome in pediatric patients with
IBD and lung-transplant recipients, show exciting new finding about engineering the microbiota to help with
hyperammonia, and finally investigate a possible limitation about using microbial communities as
therapeutics. Together this body of work provides insights into the assemblage of tiny organisms that live
within us, constantly contributing.
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ABSTRACT 
 
THE IMPACT OF TINY ORGANISMS: MICROBIAL COMMUNITIES AND DISEASE STATES 
Christel Sjöland Chehoud 
Frederic D. Bushman  
Gary D. Wu 
 
In the last decade, primarily through the use of sequencing, much has been learned about the 
trillions of microorganisms that reside in human hosts.  These microorganisms play a wide range 
of roles including helping our immune systems develop, digesting our food, and protecting us 
from the invasion of pathogenic organisms. My thesis focuses on the characterization of fungal, 
viral, and bacterial communities in humans, investigating the use of defined microbial 
communities to cure diseases in animal models, and examining the effects of human microbiome 
modifications through fecal microbiota transfers. In the first part of this thesis, I use deep 
sequencing of ribosomal RNA gene tags to characterize the composition of the bacterial, fungal, 
and archaeal microbiota in pediatric patients with Inflammatory Bowel Disease and healthy 
controls. Archaeal reads were rare in the pediatric samples, whereas an abundant amount of 
fungal reads was recovered. Pediatric IBD was found to be associated with reduced diversity in 
both fungal and bacterial gut microbiota, and specific Candida taxa were increased in abundance 
in the IBD samples. I, then, describe my use of a variety of experimental and computational 
methods to study the viral communities of immune-compromised lung transplant recipients. 
Anelloviruses, circular, single-stranded DNA viruses, were found in all lung samples but were 56 
times more abundant in samples from lung transplant recipients as compared to healthy controls 
or HIV+ subjects. In the third part of this thesis, I describe the use of defined microbial 
communities in mice, and its ability to reduce the production of ammonia long term and mitigate 
hepatic encephalopathy. This was shown to be true in both mice on a normal protein diet or a low 
protein diet. Last, I investigate the transfer of viral communities between humans through FMT 
  vii 
and characterize features associated with efficient transmission. A case series where feces from 
a single donor were used to treat three children with ulcerative colitis was used for the analysis. 
Ultimately this work showed that multiple viral lineages do transfer between human individuals 
through fecal microbiota transplants, but in this case series none of the viruses were known to 
infect human cells. In this thesis, I elucidate numerous roles for the microbiome in pediatric 
patients with IBD and lung-transplant recipients, show exciting new finding about engineering the 
microbiota to help with hyperammonia, and finally investigate a possible limitation about using 
microbial communities as therapeutics. Together this body of work provides insights into the 
assemblage of tiny organisms that live within us, constantly contributing. 
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CHAPTER 1: Introduction 
 The term “microbiome” was coined by Joshua Lederberg to describe the ecological 
community of commensal, symbiotic, and pathogenic microorganisms that live in or on human 
bodies (1). These trillions of microorganisms represent an ensemble of bacteria, archaea, 
eukaryotes, and viruses. These organisms play important roles in human development, 
physiology, immunity, disease, and nutrition. Many of these finding have been obtained over the 
last decade, in part, thanks to the development of culture-independent sequencing technology 
that allows us to investigate our microbial companions in an unbiased fashion. In this introductory 
chapter, I provide an overview of sequencing-based microbiome research, the tools used in the 
field, and the use of human stool for therapy of human disease.  
Human Microbiome Project 
 The National Institute of Health launched the Human Microbiome Project (HMP) in 2008 
(2). This $148 million endeavor sought to investigate the microbial diversity of 5 body sites: 
mouth, nose, skin, vagina, and gut, in healthy American adults. As part of this initiative, they also 
set out to sequence reference bacterial genomes, develop analytical and visualization tools, and 
standardized protocols for the entire scientific community to use. The first phase of HMP’s work 
was meant to, and has, served as the foundation for subsequent human microbiome work, 
particularly when examining differences in microbial communities between healthy and diseased 
individuals. The core questions of the HMP are: (1) is there a core human microbiome that is 
shared by all humans; (2) is there a core set of microbial functions that are shared by all humans; 
(3) to what extent does human phenotype or behavior impact the microbiome; (4) are changes in 
the microbiome causing disease; and (5) can disease be treated by altering the microbiome (3) . 
These questions have multi-faceted answers that we are still trying to answer today. 
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Analytical Tools 
Carl Woese revolutionized the field of microbiology when he described using the 
sequence of the small subunit ribosomal RNA gene (rRNA) for phylogenetic identification of 
organisms (4). The 16S rRNA, which is ubiquitously present in bacteria and archaea, and its 18S 
rRNA counterpart in eukaryotes, became the main tool used by microbiologists to explore 
microbial diversity and identify microorganisms throughout the body. DNA is typically isolated 
from stool, the main surrogate for the gastrointestinal tract’s microbiome, or other body sites 
including skin, vagina, and nose, and upper and lower respiratory tracts. 16S rRNA gene 
sequences, typically 1300 to 1600 base pairs in length, contain both conserved regions, which 
can be used for primer landing sites, as well as variable regions, which can be used for species-
level identification (5, 6). This allows us to sequence a small part of a genome but identify an 
entire organism.   
16S rRNA gene sequencing is the most commonly used method to identify bacteria when 
using amplicon-based sequencing. To identify archaeal sequences, 16S rRNA and rpoB genes 
are typically used, while for fungal sequences, 18S rRNA and Internal Transcribed Spacers (ITS) 
genes are commonly used. Since there is no gene ubiquitously present in all viruses, we cannot 
perform targeted gene sequencing for viruses. 
To perform amplicon-based sequencing, PCR reactions containing primers directed 
against conserved regions of the targeted gene are used to generate amplicons that span both 
the conserved and variable regions of the gene. Depending on the capacity of the sequencing 
technology, the amplicons can span a different number of variable regions in the targeted gene. 
The amplicons from each sample, which contain a unique barcode to distinguish the samples, are 
pooled, sequenced, and computationally analyzed.  
Computational analysis of targeted sequence data involves several stages. First, the 
reads are grouped into operational taxonomic units (OTUs) based on sequence identity. A 
representative sequence is used to represent each OTU, typically the most abundant sequence 
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or the longest sequence. OTUs can be defined at different sequencing similarity thresholds; for 
example, a 97% OTU signifies that all of its member sequences are at least 97% similar based on 
sequence identity. The representative OTU sequences are then aligned to reference sequences 
and annotated using databases such as Greengenes or Ribosomal Database Project (7-10). The 
alignments of the representative OTU sequences are also used to build a phylogenetic tree. 
Popular distance metrics, such as Weighted and Unweighted Unifrac (11, 12), rely on the 
phylogenetic distance between representative sequences when assessing differences in 
samples’ microbial compositions. Distances, based on each sample’s quantity of sequences in 
each OTU, are calculated and visualized using hierarchical clustering and ordinations (13).  
As sequencing technology continues to improve, efforts have moved from targeted 
amplification of select genes to shotgun sequencing of entire microbial communities. 
Metagenomics refers to the untargeted sequencing and analysis of DNA from a mixture of 
organisms. This is particularly useful since it can provide insight into the community’s gene 
content and corresponding pathways and metabolites. This technique involves randomly sheering 
DNA fragments and sequencing the resulting fragments (14). These resulting reads can be 
queried independently or assembled into contigs. The reads or contigs can be compared to 
databases of known genes including KEGG and COG (15-17). Programs such as metaphlan2 
utilize unique clade-specific marker genes to match reads to specific bacteria, archaea, 
eukaryotes and viruses (18). The resulting microbial community composition of each sample can 
be visualized with heatmaps, to assess abundance or proportional abundance of the 
microorganism present, or compared using hierarchical clustering and ordinations. 
 A major limitation to these methods is that we can only identify organisms that have been 
previously identified and placed into databases. A way to circumvent this is to use the contigs, or 
assembled genomes from reads. This is particularly common in the case of viruses. For viral 
analysis, we typically use experimental techniques to filter out human and bacterial cells prior to 
DNA extraction. After we have isolated DNA, we check for contaminating human and bacterial 
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DNA by quantifying beta-tubulin and 16S rRNA genes respectively. This ensure that there are at 
most low levels of human and bacteria DNA, so that the sample is mostly viral DNA (19). Then, 
after we have performed the sequencing, we take the resulting reads and assemble them into 
contigs through traditional overlap consensus methods (20), de Bruijn graph assembly (21, 22) or 
self-organizing map binning (23-25). Using the assembled contigs from all of the samples, we can 
map the reads from each sample to these contigs. This will result in a matrix of counts of 
matches; this can be analyzed and visualized as before with heatmaps, ordinations, and 
clustering methods. We refer to these contigs as “putative full or partial viral genomes”. In most 
cases, they do not have taxonomic annotations, but we can almost always predict open reading 
frames (ORFs) in the genomes (26, 27). 
 Culture-independent sequencing technology has allowed us to profile the bacterial, 
fungal, archaeal, and viral communities within healthy individuals and patients with different 
diseases. New tools need to be developed to help us continue our shift from characterization to 
testing hypotheses and finding causal links between the microbiome and disease. In the next 
section, I describe microbiome therapeutic development, in the form of fecal microbiota 
transplants, for several disorders in the clinical trials stage.  
Translating Microbiome Science into the Clinic 
 Fecal microbiota transplantation (FMT) is the infusion of a fecal suspension from a 
healthy individual into the gastrointestinal tract of a sick person. This procedure is thought to 
restore a healthy, diverse microbial gut community and treat diseases with altered commensal 
bacterial communities. FMTs are best known for their high efficacy in the treatment of recurrent 
Clostridium difficile infections but have shown promise for many other disorders including 
antibiotic-associated diarrhea, inflammatory bowel diseases, irritable bowel syndrome, metabolic 
syndrome, autoimmune diseases, allergic diseases, pulmonary-intestinal-associated 
inflammatory diseases, and genitourinary tract-intestinal-associated inflammatory diseases (28). 
Up until recently, FMTs were exclusively performed through enemas, nasogastric tubes, 
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colonoscopy, endoscopy, or sigmoidoscopy. Industry has now developed orally-administrable 
capsules filled with fecal suspension or freeze-dried preparations, to allow more convenient 
delivery for patients (29, 30). 
History of FMT 
 Literary evidence for FMTs dates back to 4th century China. Ge Hong, a traditional 
Chinese medical doctor, described positive results from the use of human fecal suspension by 
mouth for patients who had food poisoning or severe diarrhea (29, 31). In 16th century China, Li 
Shizhen describes using fermented fecal solution, fresh fecal suspension, dry feces, and infant 
feces to treat severe diarrhea, fever, pain, vomiting, and constipation (32). A 17th century Swedish 
text also describes veterinarians transplanting microorganisms from healthy to sick animals (33, 
34). Since the 1950s, FMT have been used in the United States sporadically without much 
regulation (35-37). Since the early 2010s, interest in FMTs has dramatically increased with many 
studies assessing its efficacy for a wide variety of diseases (38); this has resulted in several FDA 
regulation and enforcement policies surrounding FMTs.  
FMT and C. difficile 
 The first rigorous randomized controlled trial utilizing FMTs was published in January 
2013 and showed 93.8% efficacy rate for FMTs to treat recurring C. difficile infections (37). The 
spore-forming C. difficile bacterium becomes more abundant after long-term, continued use of 
antibiotics. C. difficile produces toxins which cause the patient to suffer from diarrhea and colonic 
disease, and can lead to death (39). Restoring a person’s microbiome with diverse 
microorganisms through an FMT provides an environment where other bacteria can better 
outcompete C. difficile, effectively reducing it back to healthy levels (40).   
IBS and IBD 
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 Given the immense success of FMT for treating C. difficile, FMT have been investigated 
for several other diseases including refractory diarrhea-dominant irritable bowel syndrome (41, 
42) and Inflammatory Bowel Diseases (IBD). IBD is a chronic relapsing inflammatory disorder of 
the intestine and includes both Ulcerative Colitis (UC) and Crohn’s Disease (CD). Many studies 
have implicated the intestinal microbiota in the pathophysiology of IBD, suggesting that bacterial 
dysbiosis in a susceptible host may lead to inflammation through a complex interplay of factors 
(40, 43-45). Since mouse models have shown bacteria can activate T-regulatory cells and directly 
contribute to the reduction in inflammation (45-48), it is thought that FMT can be used for IBD to 
modulate the gut microbiome and improve the existing pathologic inflammatory state. Studies for 
FMT and IBD have had mixed results (49). Large scale, phase 3 clinical trials are currently 
underway for both CD and UC (50, 51).  
Obesity, Type 2 Diabetes, and Non-Alcoholic Liver Disease 
Multiple descriptive analyses have suggested an association between obesity and the gut 
microbial community in both human and rodent models (52-57). Along with early work showing 
that cecal content transplants could alter adiposity in murine models (52), the seminal contribution 
to this area came from Jeff Gordon’s lab where colonization of germ-free mice with a stool from 
obese mice resulted in greater increase in total body fat than colonization with stool from lean 
mice (54, 57). Follow-up to this work has further shown causal links between the microbiome and 
obesity and have highlighted the potential contribution of microbiome-modulated immune 
responses to the development of obesity and its associated complications in both rodent models 
and large-scale human studies (53, 58-65).  
Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of chronic 
liver disease worldwide (66), is a known co-morbidity of obesity and type 2 diabetes mellitus 
(T2D) (67). Small intestinal bacterial overgrowths of Gram-negative organisms have been shown 
to promote insulin resistance, increase endogenous ethanol production and induce choline 
deficiency, all factors implicated in obesity, T2D, and NAFLD (68). Several clinical trials are 
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currently underway where subjects receive FMT, via capsules or nasoduodenal tube, from lean, 
metabolically healthy donors, and the resulting effects on body weight, insulin sensitivity, and/or 
amount of fat in the liver are studied (69-71). Given FMT’s success in treating refractory C. 
difficile infections, clinical trials are currently underway to investigate FMTs’ efficacy in treating 
patients with IBD, IBS, obesity, type 2 diabetes, and NAFLD.  
Thesis Outline 
Sequencing has greatly increased our ability to query entire communities of microbial 
DNA in any part of the human body and investigate how they change with different diseases. In 
the first part of this thesis, I investigate the bacteria, archaea and fungi in healthy children and 
children with IBD using next-generation sequencing technology. I assess overall diversity and use 
the abundance of the microorganisms to predict healthy versus IBD. I also investigate 
correlations between the microorganisms. This was all done to better understand the relationship 
between the fungi and bacteria in the context of IBD.  
In the second part of this thesis, I deploy novel computational methods to investigate 
DNA viruses within the respiratory tract. Metagenomic analysis of allograft bronchoalveolar 
lavage from lung-transplant recipients was compared to healthy and HIV+ subjects. The viral 
communities were compared to the bacterial members and the patient metadata.  
Chapters 4 and 5 describe the use of rodent models to assess the efficacy of engineered 
microbial communities in reducing long-term production of ammonia and mitigating 
hyperammonemia-associated neurotoxicity and encephalopathy. In the intestine, bacterial urease 
converts host-derived urea to ammonia and carbon dioxide; thus, we investigated durability of an 
engineered community lacking urease capabilities, both in mice on a normal protein diet or a low 
protein diet, and the long-term effects the new community had on fecal ammonia levels, mortality, 
and neurobehavioral deficits in acute and chronic liver injury models. 
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In the last part of thesis, I ask an important question concerning viral transfer during FMT. 
Using a sample set of 3 subjects who each received between 22 and 30 FMTs, I search for 
viruses present in the donor but not in any of the recipients’ pre-FMT samples. I further develop 
the viral analysis pipeline discussed in Chapter 3 and investigate similarity between viruses 
transferred to assess if certain viral families or viral genes make viruses more likely to transfer. 
This work is important when assessing the safety of FMT, in particular given its increased use.  
Overall, I leveraged recent advances in next-generation sequencing technology to 
conduct metagenomic analyses of microorganisms in several different diseases. I discuss the 
characterization of these microorganisms and how these microorganisms can be modulated to 
alleviate disease. I end by describing the viral communities that may play a role in modulating 
human gut bacterial communities.  
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CHAPTER 2: Fungal Signature in the Gut Microbiota of Pediatric Patients with 
Inflammatory Bowel Disease 
The contents of this chapter have been published as:  
Chehoud C*, Albenberg L*, Judge C, Hoffmann C, Grunberg S, Bittinger K, Baldassano 
R, Lewis J, Bushman F, Wu G. 2015. Fungal Signature in the Gut Microbiota of Pediatric 
Patients with IBD. Inflammatory Bowel Diseases Journal (PMID: 26083617). 
 
Abstract 
Inflammatory bowel disease (IBD) involves dysregulation of mucosal immunity in response to 
environmental factors such as the gut microbiota. The bacterial microbiota is often altered in IBD, 
but the connection to disease is not fully clarified, and gut fungi have recently been suggested to 
play a role as well. In this study, we compared microbes from all three domains of life--bacteria, 
archaea, and eukaryota--in pediatric patients with IBD and healthy controls. A stool sample was 
collected from patients with IBD (n=34) or health control subjects (n=90), and bacterial, archaeal, 
and fungal communities were characterized by deep sequencing of rRNA gene segments specific 
to each domain. IBD patients (Crohn’s disease or ulcerative colitis) had lower bacterial diversity 
and distinctive fungal communities. Two lineages annotating as Candida were significantly more 
abundant in IBD patients (p = 0.0034 and p=0.00038, respectively) while a lineage annotating as 
Cladosporium was more abundant in healthy subjects (p=0.0025). There were no statistically 
significant differences in archaea, which were rare in pediatric samples compared to those from 
adults. Pediatric IBD is associated with reduced diversity in both fungal and bacterial gut 
microbiota. Specific Candida taxa were increased in abundance in the IBD samples.  These data 
emphasize the potential importance of fungal microbiota signatures as biomarkers of pediatric 
IBD, supporting their possible role in disease pathogenesis. 
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Introduction  
The three domains of life--bacteria, archaea, and eukaryota--are all represented in 
human gut communities (1-5).  Numerous disorders, both intestinal and systemic, have been 
associated with alterations in microbial community structure, termed “dysbiosis” (6-8). The 
dysbiotic bacterial microbiota has been extensively characterized for the inflammatory bowel 
diseases (IBD) and Clostridium difficile infection, although the composition of the archaea and 
eukaryota domains and their interaction with bacteria has not been studied in detail. The 
pathogenesis of IBD is associated with an inappropriate and persistent inflammatory response to 
the commensal gut microbiota in genetically susceptible individuals.  In animal studies, dysbiosis 
has been associated with the development of intestinal inflammation (reviewed in (6, 8, 9)).  Many 
of the genetic risk alleles for IBD involve regulation of innate immune responses that protect the 
host from bacterial invasion or that regulate the adaptive immune system (reviewed in (10, 11)).  
In Crohn’s disease (CD), the phylum Firmicutes is commonly reduced in proportional abundance 
(12-17), notably Faecailbacterium prausnitzii (18-20) and members of the Proteobacteria phylum 
such as Enterobacteriaceae (21, 22), including E. coli (7, 17, 23) are commonly increased.   
The importance of fungi in the human gut to health or disease is not fully understood (2, 
24).  Fungi, such as Aspergillus, Histoplasma, and Cryptococcus are known to cause pathogenic 
intestinal infections.  Fungi are also part of the commensal gut microbiota.  Increases in gut 
Candida species are hypothesized to cause systemic yeast infections in immunocompromised 
patients via translocation through the intestinal barrier (25). Fungal-bacterial interactions are just 
beginning to be described (1, 5, 6, 26-28), and this may be important in IBD (2). 
 Several lines of evidence link fungi and IBD.  Innate immune receptor activation by fungi 
may augment the development of colitis.  The main pattern recognition receptors for fungi include 
Dectin-1, Dectin-2, DC-SIGN, mannose receptor, and mannose-binding lectin (29).  Dectin-1 is a 
C-type lectin receptor, which recognizes β-glucans in the fungal cell wall. A recent study (30) 
demonstrated that mice lacking Dectin-1 had increased susceptibility to chemically induced colitis 
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due to their altered responses to indigenous fungi. A polymorphism in the gene encoding Dectin-1 
(CLEC7A) was subsequently associated with a severe form of ulcerative colitis (UC) in humans 
(30).  There may also be a relationship between high dietary concentrations of yeast and 
increased disease activity in patients with CD (31).  Treatment with fluconazole, an antifungal, 
may reduce inflammation in animal models of colitis and in patients with IBD (32), and elevated 
levels of Saccharomyces cerevisiae antibodies are a biomarker for CD (33). Finally, preliminary 
studies using denaturing gradient gel electrophoresis (DGGE) suggest that there may be 
alterations in gut fungal populations associated with IBD (25, 34). 
 Alterations in the archaeal microbiota may also be relevent to IBD. Methane production 
from archaea has been shown to be altered in patients with IBD (35). Additionally, the syntrophic 
interaction between archaea and fermentative bacteria leading to the increase in short chain fatty 
acid (SCFA) production (36) may have an impact on mucosal immunity via to the impact of SCFA 
on T regulatory cells and immune tolerance (37).  Studies of a modest number of subjects are 
beginning to suggest that fungi may be dysbiotic in IBD (34) as well as bacteria. 
In this study, we use deep sequencing of rRNA gene tags to characterize the composition 
of the bacterial, fungal, and archaeal microbiota in pediatric patients with IBD (n=32) and healthy 
controls (n=90), revealing a distinctive signature in the mycobiome. 
Results 
Patient cohort studied 
The bacterial component of the microbiome has been studied extensively in IBD, and is 
known to be dysbiotic (6, 8, 9, 46).  Thus, in this study, we sought to assess effects on the fungal 
and archaeal components of the microbiome.  A cross-sectional analysis was performed whereby 
a single stool sample was obtained from pediatric patients (3 to 21 years of age) with CD, UC, or 
indeterminate colitis (IC) (n=32). The diagnosis of IBD was based on endoscopic, radiologic, 
laboratory, and clinical findings.  Clinical phenotypes of all patients and their therapies are 
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described in Supplemental Table 1. Microbiome sequencing results for IBD patients were 
compared to results for healthy pediatric and adult subjects studied previously (n=90) (40). 
Reduced richness in the intestinal bacterial microbiota of patients with IBD 
We first characterized the bacterial composition of the microbiota by purifying and 
amplifying DNA using PCR primers recognizing the V1V2 region of the16S rRNA gene, and 
pyrosequencing an average of 2,864 reads per sample.  We analyzed fecal samples from two IC, 
four UC, and 26 CD patients (Sup. Table 2.1).  Reads were clustered into operational taxonomic 
units (OTUs) at 97% sequence identity, and representative sequences were aligned to databases 
for taxonomic attribution.  Comparison of data among the disease classes revealed few 
differences among groups (Sup. Figure 2.1). Most samples were dominated with Bacteroides.  A 
few had Clostridia as the dominant taxa.  
We compared a dataset from healthy adults and children to the IBD samples (40).  OTU 
composition was compared in a pairwise fashion between samples using UniFrac, and healthy 
and IBD sample sets were compared to each other using PERMANOVA.  We observed a clear 
separation between the IBD and healthy sample sets (p<0.0001) (Sup. Figure 2.2). 
We also investigated the diversity of the IBD samples and healthy controls, since 
previously several studies have reported lower diversity in IBD (15).  We assessed diversity by 
calculating the Shannon Index for each sample, and found that the IBD samples had significantly 
lower diversity compared to either healthy adult or pediatric control subjects (p-value <0.05) (Sup. 
Figure 2.3).  
Comparison of archaea in patients with IBD and healthy controls 
We compared the archaeal microbiota composition in the 32 IBD samples with 90 healthy 
controls by amplification with PCR primers selective for archaea, then pyrosequencing and 
alignment to databases.  Only three IBD samples contained detectable Methanobrevibacter (Sup. 
Figure 2.4), the major archaeal lineage in healthy adults (5). Six samples had a few reads (<5 
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reads each) mostly matching "Unclassified Archaea". Querying those reads against NCBI’s 
nucleotide database did not provide clearer taxonomic resolution. We validated these findings by 
quantitative PCR targeting Archaea, which confirmed that only three IBD samples, 
Subject004_CD, Subject006_CD, and Subject037_CD, had detectable archaea. There was a 
lower recovery of archaeal sequences from pediatric IBD samples compared to healthy adults 
(p<1X10-6), but pediatric IBD patients were not significantly different from healthy children 
(p=0.128) (Sup. Figure 2.5). This indicates that children have lower archaeal colonization than do 
adults, and that alterations in the archaeal colonization of the gut are not related to IBD. 
A distinctive fungal signature in the microbiota of pediatric patients with IBD 
 The fungal representation in the fecal samples was characterized by amplification of stool 
DNA with PCR primers targeting the fungal rRNA ITS region, followed by pyrosequencing using 
the 454/Roche platform, formation into OTUs at 95% sequence identity, and alignment to 
databases.  The ITS amplicon has been reported to have biases in recovery of certain lineages 
(47), but it does successfully capture a broad range of taxa (5, 26, 28).  Thirty-two IBD subjects 
were compared to 90 healthy adults and children (40).  IBD samples had significantly lower fungal 
diversity than healthy children (p-value <0.05) (Figure 2.1).  
Ordination analysis based on the presence or absence of fungal species revealed a 
separation between healthy and IBD pediatric subjects (p=0.004) (Figure 2.2).  Samples from 
healthy adults overlapped with both pediatric groups (data not shown). Ordination based on the 
abundance (rather than presence/absence) of each fungal species also showed separation 
between healthy and IBD pediatric subjects (p=0.044) (Sup. Figure 2.6).  A focused analysis of 
CD only, in which the IC and UC patients were excluded, also revealed significant separation 
between healthy and IBD pediatric subjects (Sup. Figure 2.7 p< .0001). 
 Next, we investigated whether fungal representation differed in IBD and healthy control 
samples (Sup. Figure 2.3). The most commonly observed order was Saccharomyetales, which 
contains the genus Candida. IBD samples averaged 2,675 Candida sequences (proportionally 
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72.9%) while healthy controls averaged 1,320 reads (proportionally 32.9%) (p=0.0107 based on 
read counts). Healthy adults had slightly higher, non-significant average proportions of Candida 
than did pediatric healthy subjects (1428 reads (37%) vs. 1055 reads (23%); p=0.535 based on 
read counts).  
The Candida reads were categorized in 97 different OTUs with the majority belonging to 
one OTU (genbank ID: KP132001) (Figure 2.4A). This OTU annotates as single species, which 
has previously been given multiple different names, including Pichia jadinii, Candida utilis, 
Cyberlindnera jadinii, Torula yeast, and Candida guilliermondii var. nitratophila. This OTU was 
significantly enriched in pediatric IBD patients (p-value<0.01 using raw reads or proportion for 
both pediatric IBD versus all healthy (adult and pediatric) and pediatric IBD versus pediatric 
healthy). A second Candida OTU (genbank ID: EF197997), annotating as Candida parapsilosis, 
was also more common in the pediatric IBD samples (Figure 2.4B, p-value <0.01 based on 
number of reads).  A third OTU (genbank ID: KJ596320), annotating as Cladosporium 
cladosporioides, was more common in healthy subjects (pediatric or adult healthy versus 
pediatric IBD, p-value <0.01 based on number of reads; Figure 2.4C). 
A microbial signature for pediatric IBD 
Random Forest, a supervised machine-learning algorithm, was used to generate a 
classifier capable of sorting IBD and healthy controls based on microbial community composition. 
Classifiers were developed comparing pediatric IBD to pediatric healthy (Figure 2.5A), and 
pediatric IBD versus pooled adult and pediatric healthy controls (Figure 2.5B).   Classifiers were 
compared that used bacterial 16S rRNA gene data only, fungal ITS sequence data only, or both. 
The models successfully partitioned the pediatric samples by disease status (Figure 
2.5A) and partitioned all healthy controls (children and adults) from IBD children (Figure 2.5B). 
For pediatric samples, the16S or ITS OTUs used alone showed a median accuracy of 90% and 
83% respectively, while the combination of OTUs showed greater than 93% accuracy. The 
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bacterial OTUs that could best distinguish IBD patients from healthy controls annotated as 
Bacteroides, Parabacteroides, and Faecalibacterium prausnitzii.  For fungi, the classifier was 
dominated by OTUs annotating as Pichia jadinii/Candida utilis.  The full list of distinguishing taxa 
is presented in Supplemental Tables 2.3-2.6.  
Bacterial and fungal correlations in IBD 
 Two-sided, Pearson tests were used to measure correlation between bacterial and fungal 
OTUs across IBD samples. Of the 128 bacterial OTUs tested, 33 showed FDR-corrected, 
significant (p-value <0.05) correlation with at least one fungal OTU (Figure 2.6). The most 
commonly found fungal species in IBD subjects, Candida OTU KP132001, did not correlate 
strongly with any bacterial species. Many more significant correlations between fungal and 
bacterial OTUs were detected in healthy subjects (Sup. Figure 2.8).  Evidently fungal and 
bacterial species co-vary, but this was not prominently associated with the lineages implicated as 
important in IBD in these subjects. 
Discussion 
Here, we analyzed the composition and diversity of the fungal, bacterial and archaeal 
microbiota in pediatric IBD patients compared to healthy controls.  In contrast to the many studies 
of the bacterial component of the gut microbiota, there is relatively little known about the fungal 
and archaeal microbiota and their roles in IBD.  Fungi and archaea are known to be normal 
components of the gut microbiota (1, 4, 5, 48).  In this study, we recovered abundant fungal reads 
from both IBD patients and healthy controls. In contrast, archaea were rare in the pediatric 
samples.  The potential importance of fungi in IBD is well recognized.  Antibodies to baker’s yeast 
(Saccharomyces cerevisiae), termed ASCA, are detected more frequently in patients with CD 
than in healthy controls or in patients with UC (29-69% of patients with CD (33) (49-51)).  The 
fungal antigen recognized is thought to be phosphopeptidomannan of the Saccharomyces 
cerevisiae cell wall (52). ASCA positivity may precede the development of IBD (53), and ASCA 
are found more commonly in healthy relatives of patients with CD (54).  The difference in ASCA 
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prevalence raises the possibility of a differential fungal microbiota in patients with CD versus 
healthy individuals, and our data documents such a difference.  
 Although the ASCA epitope is associated with S. cerevisiae, it is also associated with 
Candida albicans (55) and potentially other related yeasts. Candida colonization has been 
associated with multiple diseases of the gastrointestinal tract including CD, UC, esophagitis, oral 
mucositis, and even gastric ulcers (56).  Candida strains colonize gastric ulcers, particularly when 
the ulcers are large or perforated (56) and candida esophagitis responds to antifungal therapy 
demonstrating the role of Candida colonization in the pathogenesis of inflammatory processes.  
Increased colonization with Candida in IBD might be a consequence of mucosal or immune 
system alterations as well as the use of antibiotics(28).  The health consequences are unknown 
but may be adverse. 
We found three fungi with differential abundance in IBD patients versus healthy controls.  
Fungal phylogeny is in a state of transition, so species level attributions are not fully secure.  For 
example, until recently, sexual forms (teleomorphs) were commonly placed in separate genera 
from asexual forms (anamorphs) of the same fungal organisms (57).  We found one Candida 
OTU (genbank ID: KP132001) that was more abundant in patients with IBD, which has been 
associated with five named species, including Pichia jadinii, Candida utilis, Cyberlindnera jadinii, 
Torulopsis utilis, and Torula utilis (58), illustrating the challenges of current fungal taxonomy.  A 
common name for this group is Torula yeast.  In its inactive form, Torula yeast is widely used as a 
flavoring which imparts a savory taste to soups, sauces, and snack products (59). Possibly the 
pediatric subjects with IBD were eating diets more enriched in Torula yeasts, though there is no 
universal diet for patients with IBD, so this seems unlikely.  Patients with IBD frequently identify 
dietary components that cause increased symptoms and so follow restricted diets when the 
disease is active, but most subjects studied here had relatively low disease activity scores and so 
were not expected to be on specialized diets.  Also, a review of dietary records kept by the 
patients in our study did not reveal an obvious bias towards the consumption of foods rich in 
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Torula yeast (data not shown). The second explanation is that there is truly increased Torula 
yeast colonization in patients with IBD, which at present seems more likely. Members of the 
fungal genus Pichia can be pathogens in humans, especially in immunocompromised hosts (60), 
Pichia species may also lead to enteritis in animals (61, 62), and pathogenesis by Candida 
species is well described.  Further study is needed to clarify whether colonization is related to 
disease pathogenesis or whether it is a consequence of gut inflammation or immune suppressive 
therapy. 
We found a second Candida OTU (genbank ID: EF197997) that was more abundant in 
patients with IBD, and a Cladosporium cladosporioides OTU (genbank ID: KJ596320) that was 
more abundant in healthy controls. All of the IBD patients in our cohort were undergoing various 
therapies, so it is not clear whether these taxonomic changes were associated with the IBD itself 
or were a consequence of treatment, for example immunosuppression (63).  Other Candida 
yeasts, in contrast, are used as probiotics (64), raising the possibility that the yeast lineages 
present contribute a mixture of positive and negative influences.  
 Studies in animal models suggest a functional role for fungi in intestinal inflammation. 
Mice lacking the Dectin-1 receptor, a pattern recognition receptor known to identify fungi, were 
more susceptible to colonic inflammation in a dextran sodium sulfate (DSS) colitis model (30).  
Administration of Candida tropicalis resulted in a more severe DSS-induced colitis in this model, 
and treatment with fluconazole, an anti-fungal agent, reduced disease(30).  Another PRR, 
SIGNR3, was recently found to be involved in recognizing fungal commensals. Mice lacking 
SIGNR3 also exhibit increased intestinal inflammation upon exposure to DSS (65).  Additional 
investigation is needed in humans to determine the mechanisms responsible for the observed 
alterations in the fungal microbiota in patients with IBD and the role they may play in disease 
pathogenesis via pattern recognition receptors. 
 To probe distinctive lineages in health and disease, and to develop noninvasive 
biomarkers, we developed a Random Forest classifier to sort patients with IBD versus healthy 
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controls.  Using a combination of bacterial and fungal OTUs allowed greater than 93% accuracy 
in distinguishing samples. The currently-available biomarkers focus on the evaluation of patients 
already diagnosed with IBD such as differentiating CD from UC, differentiating quiescent from 
active disease, and predicting disease course (66).   Drug levels and anti-drug antibodies are also 
used as biomarkers (66).  Unfortunately, the biomarkers currently used to evaluate patients with 
symptoms of IBD, such as C - reactive protein, erythrocyte sedimentation rate, and fecal 
calprotectin, are not specific to IBD.  Additionally, methods are needed to establish early 
diagnosis of at-risk individuals, such as asymptomatic family members of patients with IBD.  It will 
be useful to evaluate the performance of the assay targeting both bacteria and fungi described 
here in these settings. 
 In a recently described analysis of the archaeal microbiome of healthy human subjects, 
about 45% of subjects were found to have archaea present in the stool (5).  The vast majority of 
sequences annotated as Methanobrevibacter (5).  In our study, we found only 3 pediatric patients 
with IBD with detectable Methanobrevibacter.   The previous literature has been inconsistent, with 
some studies reporting increased prevalence of methanogens or decreased methane production 
in patients with IBD (67-70) and other studies demonstrating increased methane production in 
patients with IBD (71).  The low number of pediatric IBD subjects found to have archaeal species 
from the stool in our study is consistent with a report of methane production increase with aging 
(72).  Thus our data suggest that archaeal colonization may be more characteristic of the adult 
gut microbiota. 
 In conclusion, we report that pediatric IBD was associated with decreased fungal diversity 
and also altered taxonomic composition.  We found an increased proportion of two Candida 
OTUs in IBD patients. The fungal microbiota may be important in IBD given the increased 
prevalence of ASCA and the more recent work suggesting a relationship between fungal pattern 
recognition receptors and IBD in mice.  We also report a compositional signature elucidated in the 
Random Forrest analysis that may be useful in diagnosing IBD patients.  Thus, these findings 1) 
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clarify the existence and nature of fungal dysbiosis in pediatric IBD, 2) pose the question of 
whether specific yeast lineages may be more pro-inflammatory or colonize associated with 
inflammation, 3) motivate the investigation of fungal blooms in response to treatment of IBD, and 
4) provide a signature of dysbiosis in pediatric patients potentially useful in individualized 
molecular diagnosis. 
Methods 
Subjects 
All subjects studied were from the Philadelphia area and <21 years of age (Supplemental 
Table 1).  Subjects provided written consent or, when appropriate, assent.  Subjects were 
excluded if they had been treated with antibiotics or probiotics within the two weeks prior to 
sample collection, if there was presence of an ostomy, or if they had been treated with 
supplemental nutrition (TPN, enteral nutritional therapy, or other nutritional supplements) 
accounting for more than 50% of the total caloric intake for the one week prior to sample 
collection. Pediatric Crohn’s Disease Activity Index (PCDAI) (38) or Pediatric Ulcerative Colitis 
Activity Index (PUCAI) (39) were calculated as described.  Stool samples were collected between 
February and September 2012 and kept frozen at -80° C until they were processed for DNA 
extraction.  The sequence samples obtained from the healthy pediatric and adult subjects and 
used as controls are described in (5, 40).  Briefly, healthy volunteers were screened to be free 
from any chronic disease, to have a normal bowel movement frequency, and to have a body 
mass index (BMI) between 18.5 and 35 kg/m2.  One stool sample was provided per subject and 
kept frozen at -80° C until processed for DNA extraction. 
DNA isolation  
 DNA was isolated from approximately 200 mg of stool using the PSP Spin Stool DNA 
Plus Kit (Cat #10381102, Invitek, Berlin, Germany) as per the manufacturer’s instructions. 
16S rDNA gene and ITS1 region gene sequencing  
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Isolated DNA was quantified using the Picogreen system and 50 ng of DNA was 
amplified in each PCR reaction. Primers were barcoded to label each sample as described 
previously (41, 42).  PCR reactions were carried out in triplicate using Accuprime (Invitrogen, 
Carlsbad, CA, USA).  Each reaction contained 50 nanograms of DNA and 10 pM of each primer.  
Primers annealing to the V1V2 region of the 16S bacterial gene were used for amplification. The 
PCR protocol for 16S amplicons was described previously (43).  The development of the archaeal 
specific 16S rDNA primers and ITS1 fungal primers and PCR cycling conditions are described in 
[42]. Amplified 16S rDNA and ITS1 fragments were purified using a 1:1 volume of Agencourt 
AmPure XP beads (Beckman-Colter, Brea, CA, USA).  The purified products from the stool 
samples were pooled in equal amounts and analyzed by pyrosequencing using the Roche/454 
Genome Sequencer Junior.  DNA pools were separated by amplicon type.  DNA-free water was 
subjected to the same amplification and purification procedure, and no DNA product was 
observed in agarose gels.  Sequences of oligonucleotides used in this study are in Supplemental 
Table 2. 
Sequence Analysis 
Sequence data was processed using QIIME (44), augmented by the R package QIIMER 
(http://cran.r-project.org/web/packages/qiimer). Taxonomy was assigned to the sequences using 
Ribosomal Database Project (RDP) for 16S (45) and the UNITE database for ITS. Further 
information on methods can be found in the Supplemental Information.  
We fit a Random Forest model to predict health versus disease (IBD) using 16S bacterial 
OTUs, ITS fungal OTUs, or a combination of the two. One thousand bootstrapped iterations were 
performed to obtain an estimate of the misclassification rate. The classification error rate was 
compared to guessing, e.g. if the dataset consisted of 32 subjects with IBD and 68 healthy 
subjects, a sample would be randomly classified as a sample from a subject with IBD 32% of the 
time and as a sample from a healthy subject 68% of the time.  
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Bacterial OTUs with greater than 100 sequences across all IBD samples (128 OTUs) 
were correlated with ITS fungal OTUs with greater than 100 sequences across all IBD samples 
(27 OTUs). P-values were calculated using a two-sided Pearson correlation test. Bacterial OTUs 
with at least one correlation to a fungal OTU producing a Bonferroni-corrected p-value less than 
0.05 were displayed on the final heatmap. 
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Figures 
Figure 2.1. Diversity of fungal communities is decreased in IBD patients compared to 
healthy subjects. The Shannon diversity index was calculated based on the OTU-level 
classification tables. The boxplots show the distribution of diversity values for: (1) all healthy 
subjects, (2) only the adult healthy subjects, (3) only the pediatric healthy subjects, and (4) the 
pediatric IBD subjects. Each black dot represents a different subject.  *** p<0.0005 on Wilcox 
test. 
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Figure 2.2. Comparison of pediatric healthy and pediatric IBD subjects’ fungal community 
composition using principal coordinate ordination. Principal coordinate analysis was used to 
depict the relatedness of fungal communities based on presence or absence.  The axes 
represent the two most discriminating axes using the binary Jaccard index distance metric. 
Pediatric healthy subjects are depicted in cyan and pediatric IBD subjects are depicted in 
lavender.  The two groups clustered separately (p=0.004). 
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Figure 2.3. Taxonomic heatmap of fungal community members in healthy and IBD 
subjects. Proportions of fungal OTUs in adult healthy, pediatric healthy, and IBD subjects. The 
color bar on the top indicates the health status of each subject. Each column indicates a different 
subject.  The color bar on the right side indicates the average relative abundances of these 
genera in each subject.  
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Figure 2.4. Abundance of selected fungal OTUs. Barcharts showing the number of reads from 
three selected fungal OTUs: (A) Candida (accession KP132001), (B) Candida (accession 
EF197997) and (C) Cladosporium (accession KJ596320). Adult healthy subjects, pediatric 
healthy subjects, and pediatric IBD subjects are shown in red, blue, and purple respectively. A 
negative control sample (NC) that was processed alongside the samples is shown at the right in 
green. No reads matching any of the three lineages mentioned above were found in the negative 
control sample.  
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Figure 2.5. Random Forest Classification Accuracy for Healthy and IBD subjects. A random 
forest classifier was used to group samples into either healthy or IBD categories. Random forest 
accuracy (red) was compared to random guessing (blue) with misclassification rate indicated on 
the y-axis. The classifier was run using 16S bacterial OTUs, ITS fungal OTUs and the 
combination of both bacterial and fungal OTUs. Results were also compared using (A) pediatric 
healthy and pediatric IBD subjects or (B) both adult and pediatric healthy subjects and IBD 
subjects.  
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Figure 2.6. Correlations between Bacterial and Fungal OTUs in pediatric IBD. The Pearson 
correlation coefficient between fungal and bacterial OTUs in pediatric IBD patients was 
calculated. OTUs were included in this heatmap if they had greater than 100 sequences in 
pediatric IBD patients. OTUs were included if they significantly correlated with at least one other 
OTU (two-sided correlation, where the p-value exceeded 0.05 after Bonferroni correction).  
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Supplemental Information 
Supplemental Methods 
Sequence analysis 
Sequence data was processed using QIIME [1]. Sequences were quality trimmed and 
assigned to their respective sample based on their barcodes. Sequences were binned into de 
novo Operational Taxonomic Units (OTUs) using CDHIT [2]. with a 97% minimum sequence 
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identity threshold for 16S and a 95.2% minimum sequence identity threshold for ITS. The most 
abundant sequence from each OTU was selected as the representative sequence for that OTU.   
For the ITS analysis, spacer sequences of lengths 130 to 1000 nt were used for the 
analysis.  In a previous study [3], a longer minimum was used, which resulted in loss of the 
unusually short Cyberlindnera jadinii (aka Pichia jadinii and Candida utilis), which is only 142 nt in 
length.  We also note that length variation in the ITS region may have resulted in under-
estimation of the abundance of Saccharomyces cerevisiae, which has a relatively long ITS region 
(368 nt). 
Taxonomy was assigned to the representative sequences using Ribosomal Database 
Project (RDP) for 16S [4] and the UNITE database for the ITS. The bacterial sequences were 
then NAST aligned using the Greengenes' reference database [5] and used to build a 
phylogenetic tree using the using the FastTree algorithm [6]. Bacterial community distances were 
calculated between all pair of samples using Unifrac [7]. UniFrac distances are based on the 
fraction of branch length shared in a phylogenetic tree between two samples’ microbial 
communities. Weighted UniFrac incorporate the relative abundances of each OTU [8]. For the 
fungal community distances, Jaccard and abundance-weighted Jaccard indices were calculated.  
Principal Coordinate Analysis (PCoA) based on UniFrac distances was used to compare 
samples. Heatmaps that show the taxonomic distribution of each sample’s sequences were 
created using Qiimer (http://cran.r-project.org/web/packages/qiimer). Diversity was assessed 
using the Shannon diversity metric. LEFSE [9] was used to identify taxa that differed between IBD 
and healthy samples.  
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CHAPTER 3: Blooms of Anelloviruses in the Respiratory Tract of Lung Transplant 
Recipients 
The contents of this chapter have been published as:  
Young J, Chehoud C, Bittinger K, Bailey A, Diamond J, Cantu E, Haas A, Abbas A, Frye 
L, Christie J, Bushman F, Collman R. 2014. Blooms of Anelloviruses in the Respiratory 
Tract of Lung Transplant Recipients. American Journal of Transplantation (PMID: 
25403800). 
 
Abstract 
Few studies have examined the lung virome in health and disease. Outcomes of lung 
transplantation are known to be influenced by several recognized respiratory viruses, but global 
understanding of the virome of the transplanted lung is incomplete. To define the DNA virome 
within the respiratory tract following lung transplantation we carried out metagenomic analysis of 
allograft bronchoalveolar lavage (BAL), and compared to healthy and HIV+ subjects. Viral 
concentrates were purified from BAL and analyzed by shotgun DNA sequencing. All of the BAL 
samples contained reads mapping to anelloviruses, with high proportions in lung transplant 
samples. Anellovirus populations in transplant recipients were complex, with multiple concurrent 
variants. Q-PCR quantification revealed that anellovirus sequences were 56-fold more abundant 
in BAL from lung transplant recipients compared with healthy controls or HIV+ subjects 
(p<0.0001). Anellovirus sequences were also more abundant in upper respiratory tract specimens 
from lung transplant recipients than controls (p=0.006). Comparison to metagenomic data on 
bacterial populations showed that high anellovirus loads correlated with dysbiotic bacterial 
communities in allograft BAL (p=0.00816). Thus the respiratory tracts of lung transplant recipients 
contain high levels and complex populations of anelloviruses, warranting studies of anellovirus 
lung infection and transplant outcome. 
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Introduction  
Little is known about the virome of the human respiratory tract as a whole, though 
infections by individual viruses are well characterized. For the case of lung transplantation, viral 
infection is a major complicating factor impacting graft survival rates (1-4). Respiratory infections 
with known viruses can cause direct lung injury or increase risk of graft failure, as in the case of 
cytomegalovirus and community acquired respiratory viruses (1, 5). Intense interest has thus 
focused on viruses in the respiratory tract and transplantation outcome.   
Today it is possible to characterize large viral populations using high throughput 
metagenomic sequencing (6-8), which has identified both well-recognized and little-studied 
viruses living in association with humans. Only a few studies have applied metagenomic 
approaches to understand viruses of the lower respiratory tract (8, 9), and none in lung 
transplantation. 
Anelloviruses are circular, nonenveloped, negative-sense, single-stranded DNA viruses 
that commonly colonize humans and show increased abundance in blood after hematopoietic and 
solid organ transplantation (10-12). The anellovirus family consists of Torque Teno viruses 
(TTVs), Torque Teno Midi Viruses (TTMDV), Torque Teno Mini Viruses (TTMV), and Small 
Anelloviruses (SAVs), each of which has multiple subtypes (12, 13). Their small genomes (2.3-
3.8 kb) consist of three to four open reading frames and a highly conserved untranslated region 
(UTR) (12)_ENREF_8. These viruses are ubiquitous in the human population and have not yet 
been causally linked with any human disease (12, 13). Diverse types of anelloviruses have been 
found in various organs, tissues, and cell types (12, 14-16). 
In the respiratory tract, TTV was recently identified in bronchoalveolar lavage fluid from 
28% of individuals with acute exacerbations of idiopathic pulmonary fibrosis (IPF), but not those 
with stable IPF, and in a quarter of individuals with acute lung injury (17).  In the upper respiratory 
tract, elevated levels of TTV have been found in nasal secretions from children with respiratory 
diseases, and correlated with disease severity (15, 16). In HIV-infected patients, plasma 
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concentrations of anelloviruses increased during progression to AIDS (18) and decreased 
following therapy (19). TTV viremia was reported to increase following autologous hematopoietic 
stem cell transplantation, and then return to baseline levels following immune reconstitution (10). 
Recently, TTV levels in blood were shown to increase in association with immunosuppression 
following lung and heart transplantation (11). The association between TTV levels and immune 
status has led some authors to propose that anelloviruses genome copy numbers may serve as 
an empirical measure of successful immune suppression (10, 11, 19). 
  We report here the first study to apply viral metagenomics to understand the lung virome 
in lung transplantation. We first used Illumina metagenomic sequencing to characterize lung DNA 
viromes from lung transplant recipients, along with another immunologically impaired group, HIV-
positive individuals. This showed that anellovirus sequences were prominent in BAL from 
transplant recipients, and revealed the presence of complex populations with multiple concurrent 
variants. Based on these metagenomic data, we then quantified anellovirus levels within the 
lungs and upper respiratory tracts of lung transplant recipients, HIV+ subjects, and healthy 
individuals using Q-PCR, demonstrating high levels of anellovirus DNA in BAL and OW of lung 
transplant recipients. Our findings demonstrate metagenomic detection and genetic 
characterization of the allograft virome, which is then followed by broader quantitative analysis. 
We also compared metagenomic data on bacterial populations, and found that high levels of 
anelloviruses correlated with dysbiotic bacterial communities, revealing covariation among 
microbiome constituents. 
Results 
BAL and OW samples were collected from 1) lung transplant recipients undergoing post-
transplant bronchoscopy, 2) HIV+ individuals without lung disease or respiratory symptoms, and 
3) healthy control subjects (20, 21) (Sup. Tables 3.1, 3.2, and 3.3). VLPs were purified from BAL 
and OW, followed by concentration and treatment with nucleases to eliminate non-encapsidated 
nucleic acids (Figure 3.1). DNA was then purified from each sample. To verify selective reduction 
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in human and bacterial cells, two BAL samples were analyzed using Q-PCR to quantify bacterial 
16S rRNA gene copies or human beta-tubulin gene copies. Copies of bacterial 16S DNA 
decreased from 3000 copies/ng in unfractionated BAL to 80 copies/ng after viral particle 
purification (38-fold reduction). Human beta-tubulin DNA was detected at 925 copies/ng in 
unfractionated BAL but became undetectable after purification (>900-fold reduction).  
Metagenomic sequencing of lung transplant and HIV+ samples 
We first applied metagenomic analysis to viral DNA from six lung transplant and three 
HIV+ BAL samples. DNA from viral preps was subjected to whole genome amplification and then 
shotgun sequenced using the Illumina MiSeq platform (2 x 250 bp reads) (Table 3.1). Up to 3.4 
million reads per sample were generated, for a total of 5.42x109 bp of sequence data. Reads 
were filtered and trimmed to remove low quality sequences, and human reads were identified and 
removed. Reads were then aligned using BLAST to the NCBI viral database (Table 3.1 and Sup. 
Table 3.4).  
Of reads assigned to reference viruses, the majority (>68%) mapped to anelloviruses, 
which included Torque Teno viruses, Torque Teno Mini viruses, Torque Teno Midi viruses, and 
Small Anelloviruses (Table 3.1, Figure 3.2A). Based on the closest match to reference viruses, a 
wide variety of anelloviruses were present within the lungs of lung transplant subjects, while 
substantially fewer anellovirus reads were detected in lungs of HIV+ individuals (Figure 3.2A). 
Furthermore, diverse anelloviruses were present in single individuals, especially in the lung 
transplant recipients, as evidenced by reads aligning to many different TTVs, TTMVs, TTMVDs, 
and SAVs within single samples (Table 3.1). 
Other eukaryotic viruses were detected within the samples, but at much lower levels. 
These included Epstein-Barr virus (Human Herpesvirus 4) (2 reads in one sample), Human 
Herpesvirus 7 (2 reads in one sample, 36 reads in another sample), and Human Papillomavirus 
(1 read) (Sup. Table 3.4). To determine whether use of the 0.22 micron filter step during virus 
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purification may have resulted in depletion of some of the larger viruses, we compared filtration 
and centrifugation (Sup. Table 3.6). This showed that filtration resulted in reduced recovery of 
herpesviruses, but was more efficient at capturing small viruses such as human papillomaviruses 
and anelloviruses. 
A small percentage of reads (0.75% of total reads for all samples combined) aligned to 
bacteriophage genomes, predominantly phages of Enterobacteria, Salmonella, Pseudomonas, 
Streptococcus and Yersinia. When bacterophages were compared with bacterial 16S sequences 
from these subjects that were previously analyzed (31), we found representation of several of 
these bacterial lineages (Streptococcus, Pseudomonas, Staphylococcus, and Enterobacteria), 
consistent with possible phage/host pairs in our samples. 
An average of 81% of the reads did not match reference viruses in the NCBI viral 
database, a high proportion similar to results of other viral metagenomic studies (9, 32).  We 
surmise that many of these may correspond to DNA phage sequences, because phage are 
hyperabundant globally and poorly represented in sequence databases (33). Unidentified reads 
could also correspond to novel mammalian viruses or low quality reads not removed by our 
filtering strategy.  
Genetic structure of lung anellovirus populations 
Anellovirus reads were assembled into contigs for more complete analysis of 
anelloviruses community structure, using iterative deBruijn graph assembly (23). To validate 
correct contig assembly, we designed specific primer sets for three of the contigs, then PCR 
amplified 500-700 base pair regions, sequenced using the Sanger method, and assembled using 
the conventional overlap method. Assembled contigs were then aligned to the NCBI nt database 
(Figure 3.2B). Selected regions within the anellovirus contigs were 87-93% identical to the 
reference sequences, though highly divergent regions were also detected. Anellovirus open 
reading frames (ORF) 1 and 2 were identified in the three anellovirus contigs. ORF1 was 
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previously shown to encode the capsid gene and contains a hypervariable region, which may 
evolve rapidly to evade the host immune response (12). The ORF2 encoded protein was reported 
to suppress the NF-kB pathway, thereby potentially regulating the host innate and adaptive 
immune response (12, 34). 
To compare anelloviruses populations within and between individuals, a phylogenetic 
tree was generated using ORF1 sequences from reference genomes and contigs assembled 
from the Illumina and Sanger sequence data. As shown in Figure 3.3, multiple different 
anellovirus ORF1s were found within individual lung transplant patient allografts, with subjects 
exhibiting as many as 17 distinct contigs. In contrast, richness of anelloviruses was lower in BAL 
of HIV+ individuals, even though sequences were detected in all of them. Anellovirus contigs 
were mostly different between individuals (Figure 3.3). 
Quantification of Anellovirus DNA in lung and upper respiratory tract samples using quantitative 
PCR 
Given diverse anellovirus populations found in some of the transplant samples, we 
sought to quantify absolute anellovirus DNA levels in a larger group of subjects using Q-PCR.  
We used the universal PCR primers targeting the anellovirus highly conserved UTR (22) to 
generate a Q-PCR assay. These primers recognize TTVs, TTMVs, TTMVDs, and SAVs. We 
analyzed a total of 53 BAL samples from lung transplant recipients (n=38), HIV+ subjects (n=3), 
and healthy controls (n=12). To assess the upper respiratory tract, we also analyzed 24 OW 
samples from lung transplant recipients (n=12) and healthy controls (n=12). 
  As shown in Figure 3.4, anellovirus copy numbers in lung ranged widely among 
transplant recipients, with a median of 15,133 copies/ml (range=314 to 2.3x107 copies/ml). These 
levels were far higher than in lungs of healthy or HIV+ subjects (medians of 271 and 191 
copies/ml, respectively; p<0.0002 for comparison to lung transplant samples; Mann-Whitney test).  
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Quantities of anelloviruses in the upper respiratory tract were also measured in OW 
collected from lung transplant recipients and healthy subjects. As was seen in lung, anellovirus 
genome copies were significantly more abundant in the upper respiratory tract of transplant 
recipients compared with healthy controls (Figure 3.5) (median=16,700 in transplant recipients, 
range=634 to 632,759 copies/ml compared to median=1,033 in healthy; p=0.0055). When 
quantities of anellovirus were compared between lung and upper respiratory tract within the same 
treatment group, healthy subjects had significantly lower titers in their BAL compared to 
oropharyngeal wash (p=0.0068, Mann-Whitney test). However, in lung transplant recipients, 
anellovirus genome copies were higher in both sample types and not significantly different in lung 
compared to the upper respiratory tract (p=0.23, Figure 3.6). 
Comparison of anellovirus DNA levels to transplant subject metadata 
We then asked whether anellovirus levels in the transplant recipients’ lungs were 
correlated with clinical variables that might explain the high variability. We queried patient age, 
gender, time since transplant, number of immunosuppressive drugs, tacrolimus levels, 
prednisone dosing, target immunosuppression range, surgical type (single vs. bilateral lung 
transplant), use of azithromycin, cytomegalovirus status (donor and recipient), BAL bacterial 
culture results and bacterial load in BAL based on 16S rRNA gene Q-PCR, acute rejection grade, 
and pre-transplant diagnosis (suppurative vs. nonsuppurative lung disease). No significant 
associations were detected (Sup. Table 3.5). Though power was limited by the relatively small 
sample sizes, these data suggest that anellovirus replication in the lung allograft is linked to 
factors other than these clinical variables.  
 
Comparison of lung anellovirus DNA levels to the bacterial microbiome 
Finally, we asked whether there was a relationship between anellovirus DNA levels and 
composition of the bacterial microbiome in allografts. Previously, DNA was purified from whole 
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BAL, PCR ampified using primers that recognize conserved regions of the bacterial 16S rRNA 
gene, and products analyzed by deep sequencing (20). That analysis showed that lung transplant 
bacterial communities differed in composition from healthy subjects, and transplant recipients 
were commonly colonized by oral bacteria, known pathogenic bacteria, and sometimes by 
unexpected bacterial lineages. Absolute levels of bacteria were also higher than in healthy 
controls (40-100-fold). Here we compared the anellovirus titers with bacterial community 
composition among transplant recipients, and found a significant correlation (Figure 3.7; weighted 
UniFrac, p=0.032).  However, no specific bacterial lineages were significantly linked to anellovirus 
levels among transplant subjects. We then asked if the relationship between anellovirus and 16S 
bacterial composition might be linked to the degree to which the bacterial communities diverged 
from healthy controls. This analysis revealed a significant correlation between transplant BAL 
anellovirus levels and a metric measuring the divergence between the corresponding bacterial 
community and those of healthy subjects (Sup. Figure 3.1; p=0.008). Thus, high anellovirus levels 
in transplant recipients are also associated with aberrant bacterial microbiota.  
Discussion 
Here we used metagenomic sequencing to analyze DNA viruses present in the 
respiratory tract of lung transplant recipients and HIV-infected individuals. The metagenomic data 
then enabled targeted analysis of anellovirus levels in a larger cohort of lung transplant and 
control subjects. This is the first study to apply viral metagenomics to the lung transplant allograft. 
Multiple viruses infecting animal cells were detected by sequencing, including a remarkable 
abundance and complexity of anelloviruses, as well as much lower levels of papilloma viruses 
and herpes viruses. Bacteriophage were also detectable, as were unidentified sequences likely 
corresponding at least in part to phages. Our most notable finding was that the anelloviruses, 
including TTVs, TTMVDs, TTMVs, and SAVs, were greatly increased in abundance in the lungs 
and the upper respiratory tract of lung transplant recipients compared with healthy and HIV+ 
subjects. As this work was being completed, Quake and colleagues reported that anellovirus 
sequences were increased in abundance in blood in organ transplant recipients (11). Our data 
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reported here show that after lung transplantation, anellovirus sequences are abundant in the 
lung allograft itself. 
 The shotgun metagenomic sequence data enabled assembly of near-complete genome 
sequences for some of the most abundant anelloviruses, allowing the genetic nature of 
anelloviruses present to be analyzed in detail. A notable feature of transplant recipients was the 
great diversity of anelloviruses represented within single individuals. Quantifying the exact 
number of different forms is challenging and dependent on the metric chosen. Taking each 
independent contig into account, there were up to 247 contigs identified as anelloviruses within 
one sample (Tx-24). However, this may be an overestimate because some contigs are only 
partial genomes (sizes ranged from 250-3600 base pairs), though this is hard to assess 
definitively because replication-competent subviral molecules have been reported (35). Analysis 
based on viral ORF1 regions showed that up to 17 different anelloviruses were present within a 
single transplant recipient (Tx-24), indicating remarkable diversity. Some of the anelloviruses 
identified in these subjects were distant in sequence from database genomes. Such high 
divergence was confirmed in the three genomes reconstructed by Sanger sequencing, and so is 
not a result of error in Illumina sequence determination or assembly. The origin of this extreme 
diversity is unclear, but may be due in part to the known high mutation rates of single-stranded 
DNA viruses (36) combined with high virus levels likely reflecting high rates of virus replication in 
lung.  
 We found large numbers of bacteriophage sequences in our shotgun metagenomic data, 
likely due to the abundant bacterial populations in lung transplant subjects (20), but relatively few 
mammalian DNA viruses besides anelloviruses. This is likely in large part related to the near-
universal use of herpesviruses prophylaxis in transplant subjects, and relatively modest level of 
immune dysfunction based on CD4+ T cell counts in our HIV+ subjects. In addition, samples for 
metagenomic analysis were subject to multiple displacement amplification, which favors small 
circular genomes such as anelloviruses. An additional technical factor may be that the filtration 
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step used could have depleted large viruses or viral particles bound to other macromolecules, 
although reconstruction experiments suggest that the losses were modest. In addition, a large 
proportion of sequences did not match any database genomes, which is concordant with findings 
in other metagenomic virome studies (6, 9, 32). While many of these are likely novel 
bacterophages, it is possible that novel mammalian viruses may exist within those sequences as 
well. One limitation of our sample set is the relatively short elapsed time since transplant (median 
of 5 months), and it will be useful to investigate whether additional viral lineages emerge over 
longer times. 
 Anellovirus genome copy numbers in lung from Q-PCR data were remarkably different 
among transplant subjects, varying across nearly 5 orders of magnitude.  However, comparison 
to standard patient metadata did not show significant correlations with any of the clinical 
parameters queried. A recent study of anellovirus in serum following organ transplantation 
reported that anellovirus genome levels correlated with the extent of immunosuppression, 
suggesting that anellovirus DNA in blood might serve as an assay for the overall level of 
immunosuppression (11). In contrast, our subjects were receiving relatively homogenous 
immunosuppression regimens (Table S1), and we found no association with any measure of 
immunosuppression, nor with time since transplant (Table S5).  Thus, the absence of correlations 
seen here between lung anellovirus levels and clinical variables suggests that anellovirus 
replication in lung allografts may be regulated by factors that have yet to be identified.  
We compared anellovirus DNA quantification to previously determined data on the 
structure of bacterial communities, and identified a novel form of covariation. Among transplant 
recipients, BAL samples with high anellovirus levels differed from those with lower levels based 
on the bacterial 16S data. Furthermore, samples with highest levels of anellovirus were more 
divergent from the bacterial communities of healthy controls, indicating bacterial dysbiosis. This 
suggests that the anellovirus and bacterial communities may both be blooming in response to 
some common property of the host, such as loss of immune control. If so, the immune impairment 
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would not be reflected by standard clinical measures, which did not correlate with features of 
anelloviral DNA levels. The correlation between anellovirus titers and bacterial dysbiosis was 
imperfect, however, indicating that there are likely both shared and unique factors influencing viral 
and bacterial microbiota, respectively.  
 In summary, our results employing shotgun metagenomic sequencing revealed robust 
anellovirus populations in lungs of lung transplant recipients, which was then confirmed and 
quantified by targeted Q-PCR. Long-term lung transplant outcomes have been linked to prior 
infection with several other viruses (1, 2, 4). While our subjects were sampled at relatively early 
time points (median 5 months post-transplant), early post-transplant colonization with other 
microbial agents has been associated with BOS at later time points (37, 38). Thus, the finding of 
unexpected high levels of anellovirus replication within lung allografts and marked inter-subject 
variability suggest that longitudinal studies are warranted to determine whether levels of 
anelloviruses in the lung allograft are associated with, and may play a role in, transplant 
outcomes. 
Methods 
Sample collection 
Bronchoalveolar lavage (BAL) was carried out within the lung allograft on lung transplant 
recipients, most of whom were undergoing routine clinical surveillance bronchoscopy during the 
first year post-transplant (Sup. Table 3.1) as described previously (20). Oropharyngeal wash 
(OW) to sample the upper respiratory tract was collected as previously described (20). One group 
of control samples were obtained from healthy volunteers who underwent research bronchoscopy 
using the same procedure (Sup. Table 3.2). Samples from three HIV+ subjects not on 
antiretroviral therapy (CD4 T cell counts of 301, 321 and 682; Sup. Table 3.3) and a second set 
from healthy volunteers (Table S2) were obtained by bronchoscopy using a previously described 
two-scope procedure (21). The University of Pennsylvania IRB approved all procedures 
(protocols # 812748 and #810851), and subjects gave written informed consent.  
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Virus-Like Particle (VLP) purification 
Virus-like particles were purified from 1-5 milliliters of BAL or OW, depending upon 
availability. 10mM MgSO4 and 10mM dithiothreitol were added to the BAL or OW and filtered 
through a 0.22 µm filter (Millipore). The filtrate was concentrated using a 100kDa molecular 
weight cut-off filter (Amicon 20, Millipore), resuspended in 1 ml Buffer SM_ENREF_21, and 
reconcentrated. The concentrate was treated with DNase I and RNase (Roche) at 37°C for 15 
min to eliminate non-encapsidated nucleic acids, then the enzymes were deactivated at 70°C for 
5 min.  
Nucleic acid extraction and metagenomic sequencing 
Nucleic acids were extracted from virus particle preps using Qiagen’s All Prep nucleic 
acid isolation kit. Six lung transplant and three HIV+ BAL samples that had large volumes of BAL 
and detailed patient metadata available were used for metagenomic sequencing. Whole genome 
amplification was performed on these samples using the GenomiPhi V2 Amplification Kit (GE 
Healthcare). Libraries for sequencing were made using Illumina’s Nextera XT DNA Sample 
Preparation Kit with 1 ng of input DNA, generating paired-end fragments. Metagenomic 
sequencing was performed on an Illumina MiSeq instrument. 
Quantitative PCR 
Q-PCR was carried out on non-Genomiphi amplified DNA using primers targeting the 
UTR of anelloviruses from a previously-described assay (22) that we adapted to a SYBR green-
based method as described in Supplemental Methods. All samples were run in duplicate or 
triplicate and values averaged. The detection limit was 1.4 copies per reaction. 
Bioinformatics pipeline 
Paired-end reads from the MiSeq instrument were quality-trimmed and processed 
through BMTagger to remove human sequences. Non-human reads were then analyzed using 
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BLAST against the NCBI viral database. Reads were assembled into contigs by iterative deBruijn 
graph assembly using IDBA-UD (23). To verify contig assembly, contig-specific PCR primers 
were synthesized and amplification products subjected to Sanger sequencing. Dot plots were 
generated using Gepard with a word size of 10 nucleotides (24). Anellovirus ORF1 amino acid 
sequences were identified from our contigs and aligned along with 49 reference TTV, TTMDV, 
and TTMV sequences from Genbank. The phylogenetic tree was built using FastTree v2.1.3 (25).  
Further details of bioinformatic analysis are provided in Supplemental Methods. 
Analysis of 16S reads from (20) was undertaken using QIIME v1.8 (26). Operational 
taxonomic units were selected at 97% sequence similarity with UCLUST (27). Following this step, 
the seed sequences from the clustering algorithm were used as representatives for each cluster. 
Taxonomic assignments against the GreenGenes 16S database v13_8 (28) were generated 
using the default consensus method in QIIME. A phylogenetic tree was estimated by FastTree 
v2.1.3 (25) using PyNAST-aligned representative sequences (29). Pairwise UniFrac distances 
were then calculated using the implementation in QIIME. 
Statistical analyses 
Mann-Whitney tests, paired Wilcoxon signed rank tests, t-tests, and Spearman 
correlation tests were performed in R (30). 
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Table and Figures 
Table 3.1. Anelloviruses identified through metagenomic sequencing of BAL samples from 
lung transplant recipients and HIV+ individuals. 
 
 
 
  
       
 HUP1A03 HUP1B03 HUP1B07 Tx-24 Tx-34 Tx-38 Tx-49 Tx-51 Tx-52 
Total Reads (Unfiltered) 1,134,270 3,480,764 649,864 644,536 869,518 1,236,626 1,169,756 171,892 71,018 
Total Reads after Quality Trimming 1,134,256 3,480,750 649,852 644,526 869,504 1,236,620 1,169,742 171,884 71,010 
% Human Reads 0% 0% 0% 1% 0% 26% 29% 21% 14% 
% Reads Matching to Viral DB 4% 4% 5% 21% 23% 1% 10% 7% 1% 
Small anellovirus 1 0 0 0 1 2 0 0 0 0 
Small anellovirus 2 0 0 0 14 0 0 0 0 0 
Torque teno felis virus 0 0 0 0 0 1 0 0 0 
Torque teno midi virus 1 0 0 0 20 1 0 0 0 0 
Torque teno midi virus 2 0 0 0 13 1 0 0 0 0 
Torque teno mini virus 2 0 0 0 0 4 0 0 0 0 
Torque teno mini virus 3 0 0 0 0 0 5 2 0 0 
Torque teno mini virus 4 0 0 0 0 6 0 0 0 0 
Torque teno mini virus 5 0 0 0 0 0 7 0 0 18 
Torque teno mini virus 7 0 0 0 5 0 9 0 0 6 
Torque teno mini virus 8 0 0 0 0 3 2 0 0 0 
Torque teno virus 1 4 6 3 3124 10901 44 1051 128 2 
Torque teno virus 10 8 10 3 6984 10537 97 4828 513 1 
Torque teno virus 12 4 13 0 9946 222 21 2695 98 4 
Torque teno virus 14 1 4 0 480 15 290 10819 4235 0 
Torque teno virus 15 19 46 19 44356 75859 115 7173 564 3 
Torque teno virus 16 7 18 5 10860 5918 166 19424 175 0 
Torque teno virus 19 7 12 5 3102 12143 78 14768 233 2 
Torque teno virus 2 1 6 0 262 7 82 66 501 0 
Torque teno virus 27 2 0 1 1381 1046 46 1036 57 1 
Torque teno virus 28 3 3 1 211 80 11 161 6 0 
Torque teno virus 3 5 33 1 15693 59 79 19995 1202 0 
Torque teno virus 4 2 1 0 853 9 0 1114 661 0 
Torque teno virus 6 19 24 5 22153 13397 184 10487 127 6 
Torque teno virus 7 4 48 2 8714 28 20 1950 22 0 
Torque teno virus 8 20 28 79 6834 69854 868 17068 2440 24 
Torque teno virus 0 1 0 1076 3 24 970 0 0 
HIV+ Lung Transplant Recipients
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Figure 3.1. Overview of experimental design. BAL and OW samples (1-5 ml) were filtered 
through a 0.22 µM filter, concentrated on an Amicon 10 kDa MWCO filter, washed, and treated 
with DNase and RNase to yield purified virus-like particles. Select samples were checked for viral 
purity by quantifying the bacterial 16S rRNA and human β-tubulin genes using Q-PCR. 
Anelloviruses were quantified in all samples by Q-PCR. Select lung transplant and HIV+ samples 
were whole-genome amplified by multiple displacement amplification (MDA) and shotgun 
sequenced using the Illumina MiSeq platform. Bioinformatic analysis of the virome reads 
consisted of removing human reads (BMTagger) and aligning to the NCBI viral database. Reads 
were assembled into contigs, aligned to the NCBI viral database and analyzed.  
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Figure 3.2. Anelloviruses in BAL of HIV+ individuals and lung transplant recipients. A) 
Distribution of reads aligning to anelloviruses. Metagenomic sequencing reads were searched 
against the NCBI viral database and the number of combined reads aligning to each anellovirus 
calculated for lung transplant recipients (n=6) and HIV+ subjects (n=3).  B) Presence of multiple 
anelloviruses present within the lungs of lung transplant recipient Tx-24 verified by Sanger 
sequencing. For each of the three analyzed by Sanger sequencing (x-axis), similarity was scored 
versus their closest matching NCBI reference sequence (y-axis). Open reading frames were 
assigned using MacVector and are illustrated on the genetic maps under the dot plots.   
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Figure 3.3.  Diversity of anellovirus ORF1 sequences in samples from each individual 
studied. ORF1 amino acid sequences from anellovirus contigs and Genbank reference 
sequences were aligned and trimmed to generate the phylogenetic tree shown. The names of the 
reference sequences include the TTV strain name followed by the Genbank identification (gi) 
number. Clades are designated as groups, in the outer ring, as described by Okamoto et al (12, 
22). The BAL sample of origin of each ORF1 sequence is designated by the color code (key at 
right). The Shimodaira-Hasegawa (SH) score was calculated using FastTree to estimate the 
reliability of each split compared to alternate topologies (25). Local SH support values over 0.9 
are labeled as circles on the nodes of the tree. The scale bar represents the number of amino 
acid substitutions per position.  
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Figure 3.4.  Abundance of anelloviruses in BAL samples. Anelloviruses were quantified by Q-
PCR in BAL from lung transplant recipients, healthy individuals, and HIV+ individuals. Boxes 
represent the middle two quartiles for each group and whiskers are placed at the minimum and 
maximum values. Quantities were higher in lung transplant recipients compared with healthy and 
HIV+ individuals as determined by the Mann-Whitney test with Bonferroni correction: p<0.0002. 
All samples quantified were above the Q-PCR detection limit (1.4 copies per reaction). 
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Figure 3.5. Abundance of anelloviruses in OW samples. Anelloviruses were quantified by Q-
PCR in oropharyngeal wash from healthy individuals and lung transplant recipients. Anellovirus 
quantities were higher in the upper respiratory tract of lung transplant recipients compared with 
healthy individuals. Mann-Whitney test: p=0.0055. All samples quantified were above the Q-PCR 
detection limit. 
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Figure 3.6. Comparison of anellovirus quantities in lung and upper respiratory tract within 
individuals. Paired Wilcoxon signed rank tests were performed on anellovirus copies from  BAL 
and OW in A) healthy control subjects and B) lung transplant recipients. Anellovirus DNA copies 
were lower in the lung compared with the upper respiratory tract of healthy controls but not in lung 
transplant recipients (p-values: 0.0068 and 0.23, respectively). 
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Figure 3.7. Ordination based on composition of bacterial 16S sequence analysis, showing 
the relationship to anellovirus DNA copy numbers. Each circle on the plot shows data for a 
single transplant recipient BAL sample. For each sample, bacterial 16S rRNA gene tags were 
subject to deep sequencing (median 7,925 reads per sample; data published in (20)) and 
analyzed using Weighted UniFrac, which generated a set of pairwise distances among samples. 
The distances were then analyzed using Principal Coordinate Analysis (PCoA), and the samples 
plotted along the first two principal coordinates. For each sample, the anellovirus titer is 
summarized by the size of the open circle. Among these transplant recipient BALs there is a 
significant relationship between anellovirus DNA level and 16S bacterial community composition, 
which is reflected in the observation that samples with low anellovirus titers tend to appear on the 
lower left side of the PCoA plot (p=0.032; ADONIS test). 
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Supplemental Methods 
Quantitative PCR  
Q-PCR was carried out on non-Genomiphi amplified DNA isolated from BAL and OW. 
TTV primers NG779 (ACWKMCGAATGGCTGAGTTT) and 
NG781 (CCCKWGCCCGARTTGCCCCT) targeting the UTR of anelloviruses were used (1), and 
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the assay adapted to a quantitative SYBR green-based Q-PCR. Briefly, a 126 bp fragment 
from TTV was amplified by end-point PCR, TA-cloned into the pCR4 TOPO vector (Invitrogen), 
quantified by PicoGreen, and used to generate a standard curve. 10µl SYBR green FAST master 
mix (Applied Biosystems), 50µM of each primer, and 10µl standard curve or DNA (diluted 1:10) 
were added per well. PCR cycle parameters were as follows: 95°C for 90 seconds, and forty 
cycles of 94°C for 15 seconds, and 68°C for 1 minute. Melt curve analysis of amplification 
products showed a single transition suggestive of formation of a single DNA product. All samples 
were run in duplicate or triplicate and values averaged. The detection limit was 1.4 copies per 
reaction.  
Bioinformatics pipeline  
Paired-end reads from the MiSeq instrument were quality-trimmed and processed 
through BMTagger to remove human sequences. Non-human reads were then analyzed using 
BLAST against the NCBI viral database (downloaded April 2, 2013 from 
https://www.ncbi.nlm.nih.gov/genomes/Genomes Home.cgi) and the percent of each virus 
genome covered by reads was calculated. The percentage of paired reads matching the same 
virus was also calculated. Subsequently, reads were aligned to selected individual viruses one at 
a time. The alignments were performed using Bowtie2 (2) and visualized using IGV (3). A large 
number of reads (170,651 across all samples) showed a best BLAST hit from the NCBI viral 
database to a 50 base region within the RNA plant virus Physalis mottle virus. This sequence 
covered less than 1% of the genome, and also shared 100% nucleotide identity with DNA cloning 
vectors, so those sequences were removed manually from the analysis.  
Reads were assembled into contigs by iterative deBruijn graph assembly using IDBA-UD 
(4). Sanger sequencing was performed on selected contigs following PCR amplification using 
contig-specific primers to verify sequences. Dot plots were generated using Gepard with a word 
size of 10 nucleotides (5). Anellovirus ORF1 amino acid sequences were identified from our 
contigs and aligned along with 49 reference TTV, TTMDV, and TTMV sequences from Genbank. 
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Sequences were aligned using MUSCLE v.3.8.31 (6) and trimmed to include only columns with 
80% amino acid coverage. Subsequently, the 10% most variable columns were removed. The 
phylogenetic tree was built using FastTree v. 2.1.3 (7) which calculates local support values using 
the Shimodaira-Hasegawa (SH) test to estimate the reliability of each split compared to alternate 
topologies (7-10). The groups, color bars corresponding to the samples, and SH- indices were 
incorporated using iTOL (11). Groups were chosen based on clades determined by SH-indices 
(>90%) and a guide tree previously published by Okamoto et al (12).  
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Abstract 
Increasing evidence indicates that the gut microbiota can be altered to ameliorate or prevent 
disease states, and engineering the gut microbiota to therapeutically modulate host metabolism is 
an emerging goal of microbiome research. In the intestine, bacterial urease converts host-derived 
urea to ammonia and carbon dioxide, contributing to hyperammonemia-associated neurotoxicity 
and encephalopathy in patients with liver disease. Here, we engineered murine gut microbiota to 
reduce urease activity. Animals were depleted of their preexisting gut microbiota and then 
inoculated with altered Schaedler flora (ASF), a defined consortium of 8 bacteria with minimal 
urease gene content. This protocol resulted in establishment of a persistent new community that 
promoted a long-term reduction in fecal urease activity and ammonia production. Moreover, in a 
murine model of hepatic injury, ASF transplantation was associated with decreased morbidity and 
mortality. These results provide proof of concept that inoculation of a prepared host with a defined 
gut microbiota can lead to durable metabolic changes with therapeutic utility.  
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Introduction  
Dysbiosis, an abnormal and pathogenic state of the human microbiome, has been 
implicated in inflammatory bowel diseases, atherosclerosis, obesity, diabetes, colon cancer, and 
other diseases (1, 2). Fecal microbiota transplantation (FMT) is highly effective in the treatment of 
refractory Clostridium difficile infection (CDI), providing proof of principle that a human disease 
can be treated by engineering the gut microbiota (3), and further studies indicate that a healthy 
microbiota can prevent disease acquisition (4).  
Bacteria residing in the human gut produce urease, the activity of which is beneficial in 
healthy hosts but pathogenic in hosts with liver disease. Urea produced by the liver as a waste 
product is both excreted in urine and transported into the colon, where it is hydrolyzed by 
bacterial urease into carbon dioxide and ammonia. Ammonia is then (a) utilized by the microbiota 
for protein synthesis, (b) reabsorbed by the host, where it is incorporated into the nitrogen pool by 
hepatic metabolism, or (c) excreted in the feces. Mammalian genomes do not encode urease 
genes, so ammonia production results from bacterial urease activity acting on host-produced urea 
(5, 6). Ammonia is also largely responsible for the alkaline pH of the colonic luminal environment, 
acting to buffer the short-chain fatty acids also produced by the microbiota. Systemic ammonia 
levels are elevated in patients with liver injury, chronic liver disease, or urea cycle defects, whose 
hepatic abnormalities prevent the normal processing of ammonia delivered to the liver from the 
intestinal tract. Circulating ammonia is correlated with damage to the CNS in patients with chronic 
liver disease or inborn errors of metabolism, resulting in hepatic encephalopathy (HE) (7, 8).  
Current treatments for HE and hyperammonemia are inadequate (8). Antibiotics (ABX) 
traditionally used to treat HE, including aminoglycosides and metronidazole, are limited by side 
effects and concerns for safety including ototoxicity, nephrotoxicity, and peripheral neuropathy (9, 
10). Although rifaximin, a minimally absorbed ABX, has shown efficacy in the treatment and 
prevention of HE (11, 12), potential development of antimicrobial resistance with long-term use 
remains a concern. Lactulose is used to acidify feces and sequester ammonia as ammonium, but 
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lactulose is poorly tolerated, resulting in poor adherence (13). In a mouse model of 
thioacetamide-induced liver injury, a lactobacillus pro- biotic has been reported to reduce 
ammonia levels and mortality (14), but these benefits have not been extended to human studies 
(15, 16). While promising, studies of probiotic therapies in humans described to date have 
suffered from methodological limitations, did not document long-term effects, and showed 
consistently minimal effects on outcome, motivating efforts to engineer more resilient and 
effective bacterial communities.  
Here, we show that a synthetic microbial community lacking urease activity can be 
installed in the gut to reduce the production of ammonia long term and thereby mitigate HE in a 
mouse model. For proof-of-concept studies, we used altered Schaedler flora (ASF), which 
consists of 8 murine gut commensal bacterial strains that were assembled in the 1970s and 
standardized by the National Cancer Institute in 1978 (17). The strains were originally selected on 
the basis of their persistence from generation to generation in germ-free mice and their ability to 
restore a cecal morphology that is comparable to that of conventional mice. The ASF community 
is innocuous, known to have a beneficial effect of inducing immune tolerance (18), and is used by 
commercial mouse vendors to enhance the health of immunodeficient mouse strains. We found 
that ASF is low in urease activity, making it useful for the studies of metabolic engineering 
described here. Mixed results have been reported regarding the transfer of conventional 
microbiota between rodents, with some studies reporting successful transfer with repetitive 
inoculation (19), but others demonstrating that the use of ABX prevented transfer (20). We 
developed methods for purging the gut microbiota from normally colonized mice that were then 
transplanted with ASF by gavage. Transplantation of ASF was monitored longitudinally using 
deep sequencing of DNA from fecal pellets, revealing highly efficient colonization in properly 
prepared hosts. Over a 4-week monitoring period, ASF was partially displaced by selective 
colonization with environmental Firmicutes, reaching a new steady state, but fecal ammonia 
levels remained low. The engineered gut community was tested in thioacetamide (TAA) models 
of acute and chronic liver injury (Figure 4.1A), in which we demonstrate that it reduced fecal 
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ammonia levels, mortality, and neurobehavioral deficits. These results show that transplantation 
of a defined minimal microbial community can alter metabolism in a predetermined fashion by 
establishing a new gut microbiome, resulting in therapeutic benefits in disease models.  
Results 
Transplantation of ASF into previously colonized mice 
 The original ASF was composed of 8 bacterial strains. Over time, ASF has been 
maintained in laboratory mice by fecal-oral transmission associated with cohousing in gnotobiotic 
isolators. Thus, the composition of the ASF donor material used here was first characterized by 
DNA isolation and shotgun metagenomic sequencing (16.9 Gb). Alignment to draft genome 
sequences of ASF strains (21) documented the presence of 7 of the 8 original strains in our 
samples (Figure 4.1B). Parabacteroides (ASF519) was the predominant lineage present in 
pellets. Additional ASF strains consisted of roughly even proportions of Clostridia (ASF356, 
ASF492, ASF500, ASF502) and Mucispirillum schaedleri (ASF457), accompanied by low levels 
of Lactobacilli (ASF361). No high-quality read pairs mapped concordantly to strain ASF360. In 
addition to ASF strains, 11% of reads mapped to the mouse genome, and a small fraction of 
alignments mapped to probable artifacts including cloning vectors, metazoans, and additional 
bacteria. We conclude that the bacteria in our donor material were mostly or entirely ASF strains.  
To assess the persistence of ASF in mice housed under non-sterile conditions, 
sequential fecal pellets were collected from 10 ASF-colonized mice that were transferred to 
conventional SPF housing, DNA was purified from pellets, and the abundance and types of 
bacteria present were assessed by quantitative PCR (qPCR) and deep sequencing of 16S rRNA 
V1V2 gene segments (Sup. Figure 4.1). Copy numbers of 16S sequences per gram of stool 
showed roughly similar abundance for ASF and conventionally colonized mice. Six of the eight 
ASF strains were resolved at the depth of sequencing performed.  
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ASF519 (Parabacteroides) accounted for approximately 75% of sequence reads at the 
time of transfer of the mice. After approximately 2 months under nonsterile conditions, ASF519 
remained the dominant taxon, and non-ASF taxa accounted for almost half of the sequence 
reads. Evidently, ASF lineages persisted but did not entirely exclude other bacteria.  
We reasoned that reduction of the endogenous microbiota would promote the transfer of 
ASF, so we investigated the response of conventional microbiota to the oral delivery of 2 non-
absorbable ABX, neomycin and vancomycin. The 16S rRNA gene copy number was reduced by 
approximately 4 logs within 72 hours of oral ABX initiation (P < 0.0001 for days 0, 1, and 2 
compared with the mean of days 5–15), then returned to baseline 5 days after discontinuing ABX 
(Figure 4.1C; P = 0.36 for comparison of ABX versus control at day 21), paralleling previous 
studies (22, 23).  
Fecal slurries obtained from ASF-colonized mice (Taconic) were then gavaged into 
conventionally housed recipients for 7 days following a 72-hour pretreatment with oral ABX and a 
12-hour intestinal purge using polyethylene glycol (PEG) (pretreatment with ABX and PEG is 
henceforth termed “prepared”). PEG was used in our gut-cleansing protocol, because the use of 
a purgative will likely be necessary to reduce bacterial load in the human intestinal tract due to 
high biomass. For comparison, ASF transplants were carried out on conventional mice without 
pretreatment and on germ-free mice. Mice that were treated with ABX and PEG and 
subsequently transplanted showed normal numbers of bacteria by 16S qPCR copy numbers 
within 10 days (data not shown).  
Longitudinal fecal samples were analyzed by deep sequencing of 16S rRNA gene tags, 
then the proportions of bacterial lineages detected were plotted as heatmaps, in which each row 
shows a bacterial lineage and each column a fecal specimen (Figure 4.2). Conventional mice that 
were not pretreated showed no increase in ASF lineages, despite ASF gavage (Figure 4.2, 
Conventional + ASF gavage). A few preexisting lineages were present that were indistinguishable 
from ASF using the V1V2 16S sequence window, but these did not increase in abundance after 
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ASF gavage. A second group of mice (discussed above) were colonized with ASF from birth and 
then moved to the non-sterile facility. These mice had high levels of ASF519 and detectable 
levels of 4 other ASF strains (Figure 4.2, ASF-colonized).  
These groups were then compared with (a) germ-free mice gavaged with ASF (referred 
to herein as germ-free/ASF mice); and (b) conventional mice pretreated with ABX and PEG and 
gavaged with ASF (referred to herein as prepared/ASF mice) (Figure 4.2, Germ-free + ASF 
gavage and Prepared host + ASF gavage). Prior to ASF gavage, both the germ-free animals and 
ABX-treated animals showed high levels of Lactococcus, a lineage found at high levels in mouse 
chow (22), indicating that endogenous gut bacteria were mostly or entirely absent. Gavage of 
these animals with ASF resulted in establishment of ASF lineages that persisted for the duration 
of the sampling period. The communities were again dominated by ASF519.  
Longitudinal evolution of the transplanted ASF community 
 Persistence of the transplanted ASF community was quantified using segmental 
regression, plotting time against the proportion of ASF in each sample (Figure 4.3A). 
Prepared/ASF mice and germ-free/ ASF mice transferred to non-sterile conditions were 
compared and found to behave similarly. Initially, ASF comprised the majority of the community. 
After transfer, the proportion of ASF slowly declined, constituting approximately 45% of the gut 
community after 34 days (Davies’ test for a change in the slope P < 0.001; 95% CI for the 
breakpoint was 27–41 days by segmented linear regression). After 34 days, the proportion of 
ASF strains did not decrease for the duration of the experiment (120 days; P = 0.86). 
Comparisons of community membership using unweighted UniFrac analysis of the 16S rRNA 
gene-sequencing data showed that non-ASF lineages had colonized by day 14, and members 
persisted for the duration of the study (Figure 4.3B), although the final abundance of non-ASF 
lineages was not achieved until about day 30 (Figure 4.3A). Diversity of this new stable state 
measured by the Shannon index approached that of the starting community (Figure 4.3C). 
ASF519 (Parabacteroides) was the main taxon persisting in gavage from both germ-free/ASF and 
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prepared/ASF hosts after 6 weeks, constituting approximately 40% and 50%, respectively, in 
each group (Figure 4.2). As in humans, bacteria belonging to the Bacteroides genus were 
dominant taxa in conventionally housed mice (24, 25).  
The new lineages appearing after transplantation were specific (Figure 4.4). Members of 
the Bacteroidetes phylum did not recolonize after ASF transplantation, suggesting that ASF519, a 
member of the closely related Parabacteroides genus, may have occupied niches available to this 
group. Several Firmicutes lineages did colonize over time, including lineages annotated as 
Oscillibacter, Clostridium, and “other” Firmicutes (mostly of the order Clostridiales). Thus, the 
community achieved a new steady state containing both ASF and environmentally acquired 
lineages.  
ASF has minimal urease gene content and activity 
 An analysis of the complete ASF genomes showed a minimal presence of urease genes. 
No urease genes were identified in the predominant Parabacteroides ASF519. Two ASF 
members contained urease genes, ASF492 and ASF361, but both were minor members of the 
community after transplantation (Figure 4.2).  
We then characterized urease activity, which we found readily detectable in pellets from 
conventionally housed mice, but undetectable in pellets from mice colonized with ASF (Figure 
4.5A). Similar results were obtained with pellets from mice treated with oral ABX that reduced the 
bacterial load by 10,000-fold (Figure 4.5A). Intravenous delivery of 13C-urea to quantify urease 
activity in vivo through the production of 13CO2 in a breath test revealed minimal hydrolysis in 
ASF-colonized mice (Figure 4.5B).  
Transplantation of ASF into prepared hosts led to a reduction in fecal urease activity 
lasting for at least 80 days (Figure 4.5C). The novel community assembled after 30 days had low 
urease activity, even though new lineages became established in addition to ASF (Figure 4.2). 
Analysis of representative genomic sequences from these newly established genera showed that 
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Oscillibacter, Dorea, Enterococcus, and Roseburia do not encode urease genes. We found that 
Clostridium and the group annotated as “other” Firmicutes (mostly Clostridiales) were mixed, with 
some representatives encoding urease genes, while others did not. It is unknown whether the 
newly proliferating organisms lacked urease genes, or whether they encoded urease genes but 
expressed them at low levels. Thus, the net effect of ASF colonization, together with the 
establishment of additional lineages, was the achievement of a new steady state with low urease 
activity. The new community persisted over the long term, as ASF-transplanted mice showed low 
fecal ammonia levels for over 1 year in a specific pathogen–free (SPF) housing facility (data not 
shown).  
The resilience of this new community state following dietary stress was evaluated by 
placing mice transplanted with ASF on a low-protein diet similar to that used for patients with 
hyperammonemic inborn errors of metabolism (26). Fecal ammonia levels remained much lower 
than those achieved by a low-protein diet alone, an effect that was durable for several months 
(T.-C.D. Shen and G.D. Wu, unpublished observations). Another dietary stress, consumption of a 
non-irradiated diet, led to the displacement of ASF by other bacteria within weeks after FMT, with 
the predominant taxon Parabacteroides ASF519 being partially replaced by other taxa within the 
Bacteroidetes phylum (Sup. Figure 4.2). Nevertheless, the reduction in fecal ammonia levels 
compared with those at baseline remained significant for several months, even in mice on a non-
irradiated diet (Figure 4.5D). Reductions in fecal ammonia levels have been correlated with 
reductions in blood ammonia (14, 27, 28), indicating that changes in colonic ammonia production 
and/or absorption can be associated with blood levels. The reduction in fecal ammonia may alter 
levels of false neurotransmitter precursors produced by the gut microbiota and/or by the host, 
since ammonia is a substrate for both, and this would lead to reduced formation of the biogenic 
amines that are hypothesized to play a role in HE (29–31). Thus, we propose that fecal ammonia 
is a useful biomarker for response of the host to the treatment of hyperammonemia.  
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ASF transplantation reduces mortality and cognitive impairment in murine models of acute and 
chronic liver injury 
A major cause of morbidity and mortality associated with acute liver injury is the 
development of HE. Since hyperammonemia is associated with the development of HE in 
patients with impaired hepatic function (8), we asked whether the transplantation of ASF might 
mitigate the effects of acute hepatic injury induced by TAA (32) treatment. Prepared/ASF mice 
showed both a reduction in fecal ammonia levels (Sup. Figure 4.3A, Prepared + ASF) and 
reduced mortality in response to high-dose TAA compared with mice with conventional microbiota 
(Figure 4.6A). This finding was also seen in the setting of chronic liver injury in mice transplanted 
3 weeks prior to the chronic delivery of TAA at low, escalating doses for 7 weeks (Figure 4.6B). 
Compared with control mice, prepared/ASF mice demonstrated markedly reduced mortality rates 
that were maintained over the 7-week period during which hepatic fibrosis developed in both 
groups (refs. 33, 34; data not shown), consistent with a sustained reduction in fecal ammonia for 
several months after ASF transplantation.  
In mice, the TAA model has also been associated with neurobehavioral abnormalities 
resembling HE in humans (35). Using a lower dose of TAA to reduce mortality, we analyzed 
memory and spatial learning in a Y maze test (36) comparing prepared/ASF mice with mice 
transplanted with normal microbiota (referred to herein as prepared/normal microbiota mice; 
Figure 4.7 and Supplemental Figure 4.3B and 4.3C) as a control. The 80%–90% survival rates 
were similar between the 2 groups at the lower TAA dose (Sup. Figure 4.3B). Fecal ammonia 
levels were reduced in mice transplanted with ASF compared with those with normal microbiota 
(Sup. Figure 4.3C). Prepared/normal microbiota mice showed a decrease in cognitive function 
after TAA treatment, quantified as spontaneous alternations in a Y maze test, whereas 
prepared/ASF mice treated with TAA were not different from untreated controls (Figure 4.7A). 
Mice transplanted with either ASF or normal microbiota did not sufficiently differ in locomotor 
activity after TAA treatment (as quantified by the total distance traveled and number of arm 
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entries in the Y maze) to account for the difference in spontaneous alternations, although both 
groups exhibited significantly less locomotor activity compared with untreated controls (Figure 
4.7B and 4.7C). To exclude the possibility that ASF transplantation directly reduced liver injury, 
we measured plasma alanine aminotransferase (ALT) and quantified histologic evidence of 
hepatocyte necrosis (Sup. Figure 4.4, A and B). Both revealed that liver damage induced by TAA 
was not reduced by either ASF transplantation or ABX treatment. Thus, improved survival and 
behavioral performance were associated with reduced ammonia levels and not improved 
locomotor activity or liver injury.  
Discussion 
The success of FMT in the treatment of CDI establishes that transplanting a resilient 
microbial community can alter a dysbiotic microbiota and thereby treat disease. Feces, however, 
contains not only bacteria but also a multitude of archaea, fungi, and viruses, so there is concern 
for safety (37), motivating the development of defined microbial consortia for human inoculation 
that have well-characterized biological properties and respond to the gut environment in 
predictable ways. Here, we show that a defined minimal consortium of bacteria, ASF (17, 18), can 
durably reprogram the composition and metabolic function of the gut microbiota when inoculated 
into a properly prepared host. By taking advantage of the minimal urease activity in ASF, we 
provide evidence that reprogramming the gut microbiota can lead to lower fecal ammonia levels 
and mitigate the morbidity and mortality associated with liver damage.  
The endogenous gut microbiota needed to be depleted by treatment with oral ABX and 
PEG for efficient transfer of the ASF community into conventionally housed mice. After the gut 
purge, transfer was as effective as that into germ-free recipients. Tracking by sequencing 
suggested an orderly succession of lineages. After ASF transplantation, the predominant ASF519 
strain appeared at the earliest times after gavage. Mucispirillum schaedleri (ASF457) and 
Ruminococcaceae (ASF500) also appeared early on. The last to appear was the Clostridium 
species (ASF356) on day 14 in some mice, 1 week after gavaging was complete, perhaps 
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indicating the need for development of a specific niche that permitted the establishment of more 
fastidious taxa. Most mice contained a Lactobacillus strain indistinguishable from ASF361 prior to 
transplantation, so this lineage could not be tracked with the methods used. The observed 
succession may be similar to the succession of bacterial taxa in human infants, as consumption 
of oxygen by initial gut colonizers allows the expansion of bacterial clades that are obligate 
anaerobes (38, 39).  
By monitoring the composition of the transplanted ASF community over a 4-month period 
using 16S rRNA gene sequencing, we were able to assess the persistence of the community in 
the nonsterile SPF environment. The ASF community did not fully exclude other taxa. The 
community appeared to achieve a new steady state, whereby both types of transplanted hosts 
came to resemble the mice colonized with ASF from birth and housed long term in an SPF 
environment. In each of these 3 groups, Parabacteroides (ASF519) remained the dominant 
taxon. Bacteria of the Bacteroides genus commonly dominate the human and murine gut 
microbiota (24, 40–43), but new Bacteroides did not accumulate over time in ASF-colonized mice, 
suggesting that Parabacteroides may have excluded Bacteroides, reminiscent of the trade-off 
between Bacteroides and Prevotella in human gut (24, 44–46). The mechanism by which 
Parabacteroides excludes Bacteroides is unknown but, due to their taxonomic and functional 
similarities, may involve competition for limiting resources (47) such as has been shown for 
glycans and the competition between Bacteroides species in the colonic crypt (48). Over time, the 
Parabacteroides and environmental Firmicutes established a new steady state approximating the 
composition of conventional microbiota in humans and mice (40, 41, 49), possibly involving a 
syntrophic relationship between these lineages (50).  
There was a sustained reduction in fecal urease enzymatic activity and ammonia 
production upon transfer of ASF into prepared mice. There was no return of urease activity 
several months after transfer, despite a substantial increase of non-ASF taxa. A possible lack of 
urease genes in many of the Clostridium taxa that accumulated after transplantation may explain 
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the persistently reduced urease activity, although we cannot exclude other mechanisms, since 
the regulation of urease enzymatic activity is known to be complex (6).  
Production of ammonia by the gut microbiota has been implicated in host nitrogen 
balance (51–53), so there is a theoretical risk that a urease-free community might have an 
adverse effect on protein balance and growth of the host. However, we have tracked mice for 
over 1 year after ASF transplantation and observed no adverse effects on their body weight or 
mortality. ASF is acknowledged to be an innocuous bacterial consortium in mice with beneficial 
effects on immune tolerance (18). Nevertheless, additional safety studies will need to be 
performed using a humanized version of ASF in rodent models before human studies can be 
contemplated.  
In summary, given that HE is a major contributor to morbidity and mortality in liver 
disease (54), transplantation of next-generation engineered communities based on ASF, coupled 
with improved preparation of the host as described here, represents a promising approach to 
more effective therapy.  
Methods 
Animals 
Feces from CB17 SCID mice colonized with ASF (Taconic) were the source of ASF in the 
transplantation experiments. Mice in this study were maintained in a standard SPF barrier facility 
and were fed irradiated AIN-76 chow (Research Diets Inc.) containing protein as 21% of the 
kilocalories. For the nonirradiated diet experiment, we used Laboratory Rodent Diet 5001 
(LabDiet) containing protein as 29% of the kilocalories. For microbiota transfer experiments, 0.1 g 
feces was diluted 10-fold in PBS. For Figures 4.2 to 4.4, germ-free recipient mice were purchased 
from Taconic, as were the conventionally housed Swiss Webster mice used in the first 
experiment. For all other experiments, we used either male or female 8-week-old C57BL6 mice 
(The Jackson Laboratory). Pretreated conventional mice were prepared for inoculation by oral 
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delivery of ABX in the drinking water (1.125 g aspartame, 0.15 g vancomycin, and 0.3 g neomycin 
in 300 ml sterile water) for 72 hours. During the final 12 hours, the water supply was exchanged 
with a 10% PEG solution (Merck), and the mice were fasted. The mice were then inoculated daily 
with feces by oral gavage for 5 to 7 days. Fecal pellets were collected for bacterial taxonomic and 
biochemical analyses at the time points indicated in the figures (Figure 4.1C, Figures 4.2- 4.4, 
Figure 4.5A, C, and D, Sup. Figure 4.1, Sup. Figure 4.2, and Sup. Figure 4.3A and C).  
DNA isolation, qPCR, sequencing, and analysis 
DNA was isolated from stool as previously described (46, 55). Bacterial 16S rRNA gene 
sequences were PCR amplified with primers binding to the V1V2 region (46, 55) using bar-coded 
primers (56, 57). Shotgun metagenomic data were collected using the TruSeq library preparation 
method and a HiSeq instrument (both from Illumina). Sequence reads were quality controlled and 
analyzed using the QIIME pipeline with default parameters (58). Sequence data sets were 
deposited in the NCBI’s Sequence Read Archive (SRA) database (accession number 
SRP058968).  
Urease activity and ammonia assays 
Fecal ammonia levels were determined using an Ammonia Assay Kit (ab83360; Abcam). 
Fecal pellets were suspended in the assay buffer provided at a concentration of 1 mg/10 µl and 
centrifuged at 13,000 g for 10 minutes at room temperature to remove insoluble material. 
Ammonia concentration was then determined according to the kit protocol.  
Fecal urease activity was measured by suspending fecal pellets in 0.5 mM HEPES 
buffer. After sonication and centrifugation, the supernatant was incubated for 30 minutes at 37°C 
with 1 µCi 14C-labeled urea (19.9 mCi/mmol; catalog ARC-0150; American Radiolabeled 
Chemicals) in a sealed container. The air was purged into a trap containing 2.5 ml of 0.2 M 
benzethonium hydroxide in methanol (catalog 82156; Sigma-Aldrich), and 14CO2 activity was 
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quantified by liquid scintillation counting. A standard curve was generated using purified E. coli 
urease (150 IU/mg; catalog 22060744-1; BioWORLD).  
The urease breath test was performed on 4-hour fasted mice by placing them in a sealed 
glass chamber. A total of 4 cc air was withdrawn from the chamber using a gas-tight syringe after 
10 minutes and injected into 12 ml (gas-helium) Exetainer glass vials (438B; Labco) to establish a 
baseline CO2 level. The mouse was then injected via the tail vein with [
13C]urea (150 µg/g body 
weight) (CLM-311-0; Cambridge Isotope Labs). Blood was collected 15 minutes after injection to 
assess total urea and isotopic enrichment in [13C]urea. Enrichment in expired air was measured 
at 30, 60, 120, 180, and 240 minutes after injection of the labeled urea. The 13CO2/
12CO2 ratio 
was measured in gas samples with a Finnigan DELTAplus isotope ratio mass spectrometer 
(Thermo Fisher Scientific). A commercial CO2 source (Airgas) was used as the standard. The 
measurement of isotopic abundance in [13C]urea in plasma involves the elimination of CO2 from 
the sample and the subsequent conversion of urea to CO2 with commercially available urease 
(59).  
Induction of acute liver injury and hepatic fibrosis 
Mice in the high-dose TAA acute liver injury model were given a single i.p. injection of 
TAA at 600 mg/kg. In the low-dose TAA acute liver injury model, mice were given a single dose of 
TAA at 300 mg/kg by i.p. injection, with subsequent performance of the Y maze neurobehavior 
test 48 hours after TAA injection (see Neurobehavior test below). In the chronic liver fibrosis 
model, all mice were given TAA by i.p. injection 3 times weekly, with the initial 100 mg/kg dose 
being decreased to 50 mg/ kg during the first week, given the rate of morality, followed by dose 
escalation to 100 mg/kg during the second week, 200 mg/kg during the third week, 300 mg/kg 
during the fourth week, and 400 mg/kg during the fifth to seventh weeks of TAA administration.  
Neurobehavior test 
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The Y maze test was conducted to assess the rodents’ memory and spatial learning (60). 
The maze consists of 3 identical and equally spaced arms, and the natural tendency of the 
mouse is to investigate a new arm of the maze rather than return to the one previously visited. A 
mouse with a cognitive deficit would exhibit less spontaneous alternation, defined as entering all 
3 arms in 3 sequential arm entries. Control mice typically exhibit greater than 60% spontaneous 
alternation. In this experiment, mice were allowed to habituate to the testing room, where there 
were no overt visual cues, for 30 minutes prior to testing. The maze was cleaned with 70% 
ethanol before use and between trials to eliminate odor cues. A trial started when a mouse was 
released into 1 arm of the maze (same arm for each mouse). As the mouse navigated the maze, 
each arm entry was noted. At the end of the timed trial (8 minutes), total arm entries were 
summed and spontaneous alternations determined by the following formula: percentage of 
spontaneous alternations = [(number of alternations)/(total arm entries − 2)] × 100. Trials were 
video recorded as well as graded during the procedure. Image analysis software was used to 
measure the total distance traveled by each mouse during the trials.  
Statistics 
Results are expressed as the mean ± SEM. Statistical significance among 3 or more 
groups was assessed by ANOVA. A 2-tailed Student’s t test and paired-sample t test were used 
for direct comparisons between 2 groups and within groups, respectively. Tukey’s test was used 
to adjust for multiple comparisons. Kaplan-Meier survival curves were compared using the log-
rank test. A P value of less than 0.05 was considered statistically significant.  
Study approval 
All animal studies were performed with the approval of the IACUC of the University of 
Pennsylvania.  
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Figures 
Figure 4.1. Transfer of ASF into a previously colonized murine host. (A) Diagram of the 
experimental method. Ure, urease. (B) Shotgun metagenomic analysis of stool from ASF-
colonized animals used for gavage in this study. Proportions of the different ASF lineages and 
other organisms are indicated by the color key. (C) Time course of 16S rRNA gene copy numbers 
during oral ABX treatment (14 days, vancomycin and neomycin) and upon discontinuation 
ofABXonday15(n=3pergroup). *P < 0.0001, for days 0–2 compared with the average of days 5–
15 in the ABX group; **P < 0.05, between the ABX and control groups. Paired-sample t test and 
2-tailed Student’s t test.  
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Figure 4.2. Heatmap showing the relative abundance of bacterial lineages over time in 
ASF-colonized mice and controls. Rows indicate bacterial lineages as annotated on the left. 
Relative abundance is indicated by the color key at the bottom of the figure. Columns summarize 
the sequencing results from individual fecal specimens. Elapsed time in days is shown along the 
bottom. The groups studied are indicated at the top of the heatmap and include (from the left) 
conventional mice that were gavaged with ASF stool without preparation (Conventional + ASF 
gavage); mice that were ASF colonized from birth, then transferred to a nonsterile SPF facility 
(ASF-colonized); mice that were germ-free, then gavaged with ASF (Germ-free + ASF gavage); 
and conven- tional mice that were prepared with ABX and PEG treatment, then gavaged with 
ASF (Prepared host + ASF gavage).  
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Figure 4.3. Development of a stable gut microbial community nucleated by inoculation 
with ASF. (A) Segmented regression analysis of communities in mice that were either germ-free 
or prepared conventional mice subjected to ASF gavage. The y axis shows the proportion of ASF 
lineages inferred from 16S rRNA gene tag pyrosequencing data. The x axis shows the number of 
days after transfer. Segmented regression analysis showed 2 phases, indicating a slow decline in 
the ASF proportion up to about day 30, followed by establish- ment of a new steady state 
consisting of approximately 40% ASF lineages. (B) Principal coordinates analysis (PCoA) 
ordination over time. Changes in community membership over time were analyzed using 
unweighted Unifrac (61). Progression of time is indicated by a gray arrow. (C) Shannon diversity 
of gut microbiota over time in the 4 hosts described in Figure 2. n = 5 per group for Conventional 
+ ASF gavage, Germ-free + ASF gavage, and Prepared + ASF gavage. n = 10 for ASF-
colonized.  
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Figure 4.4. Comparison of non-ASF sequence reads from either Bacteroidetes or 
Firmicutes, illustrating selective repopulation with environmental Firmicutes. (A and B) 
Groups are color coded and represent change over time. n = 5 per group for Conventional + ASF 
gavage, Germ-free + ASF gavage, and Prepared + ASF gavage. n = 10 for ASF-colonized.  
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Figure 4.5. Transfer of ASF leads to a reduction in urease activity and fecal ammonia 
levels. (A) Urease activity in the feces of a conventionally housed mouse versus  
a mouse treated with ABX and a mouse colonized with ASF. (B) In vivo urease activity in 
conventionally housed (n = 5) and ASF-colonized mice (n = 5) quantified by the release of 13CO2 
after i.v. injection of 13C-urea. (C) Fecal urease activity at the indicated time points after 
transplantation of ASF into prepared mice fed an irradiated diet (n = 3). (D) Fecal ammonia levels 
before and after transplantation of ASF into prepared mice fed a nonirradiated diet (n = 5). *P < 
0.01; **P < 0.001. Tukey’s test for multiple comparisons.  
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Figure 4.6. ASF transplantation into prepared mice reduces mortality after thioacetamide-
induced hepatic injury and fibrosis. (A) Kaplan- Meier survival curves of high-dose TAA-
induced acute hepatic injury in conventional versus prepared/ASF mice (n = 15 per group). (B) 
Kaplan- Meier survival curves of chronic, thrice weekly TAA administration at low, escalating 
doses, initiated 3 weeks after ASF transplantation (n = 15 per group). Survival curves were 
analyzed by the Kaplan-Meier method using the log-rank test.  
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Figure 4.7. ASF transplantation into prepared mice restores cognitive, but not locomotor, 
deficits after thioacetamide-induced hepatic injury. (A) Spontaneous alternations after TAA 
treatment quantified by Y maze testing in prepared mice that were transplanted with either normal 
microbiota (n = 10) or ASF (n = 11) compared with untreated control mice (n = 5). *P < 0.05, by 
2-tailed unpaired Student’s t test; P = 0.04, by ANOVA. (B) Total distance traveled and (C) 
number of arm entries in the Y maze in prepared/ASF and prepared + normal microbiota mice 
after TAA treatment compared with untreated control mice. ***P < 0.001, by 2-tailed unpaired 
Student’s t test; P < 0.001, by ANOVA.  
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CHAPTER 5: Dietary Regulation of the Gut Microbiota Engineered by a Minimal 
Defined Bacterial Consortium 
The contents of this chapter will soon be published as:  
Shen T, Chehoud C, Ni J, Hsu E, Chen Y, Bailey A, Laughlin A, Bittinger K, Bushman F, 
Wu G. 2016. Dietary Regulation of the Gut Microbiota Engineered by a Minimal Defined 
Bacterial Consortium. 
 
Abstract 
We have recently reported that Altered Schaedler Flora (ASF) can be used to durably engineer 
the gut microbiota to reduce ammonia production as an effective modality to reduce morbidity and 
mortality in the setting of liver injury. Here we investigated the effects of a low protein diet on ASF 
colonization and its ability to engineer the microbiota. Initially, ASF inoculation was similar 
between mice fed a normal protein diet or low protein diet, but the outgrowth of gut microbiota 
differed over the ensuing month. Notable was the inability of the dominant Parabacteroides ASF 
taxon to exclude other taxa belonging to the Bacteroidetes phylum in the setting of a low protein 
diet. Instead, a poorly classified yet highly represented Bacteroidetes family, S24-7, returned 
within 4 weeks of inoculation in mice fed a low protein diet, demonstrating a reduction in ASF 
resilience in response to dietary stress. Nevertheless, fecal ammonia levels remained significantly 
lower than those observed in mice on the same low protein diet that received a transplant of 
normal feces. No deleterious effects were observed in host physiology due to ASF inoculation 
into mice on a low protein diet. In total, these results demonstrate that low protein diet can have a 
pronounced effect on engineering the gut microbiota but modulation of ammonia is preserved. 
Introduction 
The gut microbiota responds to multiple environmental stressors such as diet [1-3], 
antibiotic use [4], inflammation of the intestinal tract [5], and infection of the host with enteric 
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pathogens [6]. By studying the gut microbiota in pediatric patients with Crohn’s disease, we have 
recently shown that the effects of these factors may be independent even if present 
simultaneously [7]. Amongst these, the impact of diet has received considerable attention as a 
potential modifiable factor that shapes the composition and/or function of the gut microbiota to 
prevent and/or treat disease [8]. The high-level efficacy of fecal microbiota transplantation (FMT) 
in the treatment of Clostridium difficile infections (CDI) is proof of concept that inoculating a host 
with a consortium of microbes has a meaningful effect on the composition of the gut microbiota 
[9]. The use of feces could be considered an untargeted approach with potential risks [10], but 
growing evidence suggests that the use of defined microbial consortia could be developed to treat 
disease [11, 12]. We have recently shown that the gut microbiota can be durably reconfigured to 
reduce fecal urease activity and ammonia production through oral inoculation of Altered 
Schaedler Flora (ASF), a defined microbial consortium that contains minimal urease gene content 
[12]. ASF comprises 8 murine gut commensal bacterial strains assembled in the 1970s and 
standardized by the National Cancer Institute in 1978 [13]. It is now commonly used to create 
gnotobiotic mice and/or to enhance the health of immunodeficient mouse strains.  
Examples of co-metabolism between the gut microbiota and its mammalian host requiring 
host-derived substances include bile acids, mucous, and urea. The latter is particularly important 
for nitrogen flux between the host and the gut microbiota [14, 15]. As the primary source of 
nitrogen, dietary protein is essential to the synthesis of nucleic acids, amino acids, and other 
nitrogenous compounds. The catabolism of dietary protein by the host leads to hepatic formation 
of urea, a nitrogenous waste product that is excreted through the urine or delivered into the colon, 
where hydrolysis by bacterial urease results in the production of carbon dioxide and ammonia. 
Ammonia is a shared substrate for the synthesis of proteins, amino acids, and other small 
molecules by both the host and its microbiota. Although generally thought to be nutritionally 
beneficial to the host by enhancing nitrogen recycling, the production of ammonia by the gut 
microbiota can have deleterious effects in the setting of altered hepatic function, resulting in the 
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development of neurotoxicity [16-18]. Under such conditions, a low protein diet (LPD) can be 
used to reduce systemic ammonia levels [19, 20].  
By inoculating mice with ASF after the endogenous microbiota has been reduced through 
the use of antibiotics and polyethylene glycol (PEG), the composition of the gut microbiota can be 
durably modified in composition as well as function. Functionally, there was a long-lasting 
reduction in fecal ammonia that was effective in reducing morbidity and mortality in the 
thioacetamide model of liver injury [12]. Since (1) the absorption of fecal ammonia produced by 
the gut microbiota may be an important source of nitrogen for the host especially in the setting of 
dietary protein restriction [14], and (2) low protein diets are used clinically in patients with 
hyperammonemic inborn errors of metabolism [21], there are a number of questions about the 
impact of diet on the engineering of the gut microbiota to reduce ammonia production. What is the 
effect of a LPD on the ability of a defined bacterial consortium to engraft into the gut? Does a LPD 
have an effect on the composition of the engineered microbiota? Will the ammonia reduction by 
microbiota engineering be sustained and exhibit lower levels than those achievable by a LPD 
alone? And lastly, will a significant reduction in gut microbiota ammonia production be deleterious 
to the host on a LPD?  
Here, we address these questions by inoculating mice on a LPD with either feces from 
conventionally-reared mice (Normal Feces, or NF) or with ASF, monitoring the resultant 
composition of the gut microbiota over time by 16S tagged sequencing, assessing functionality by 
quantifying fecal ammonia levels, and investigating the impact on the host by metabolic profiling. 
Although a LPD has no effect on the ability of ASF to engraft into the gut of the host upon 
inoculation, the resultant engineered state of the microbiota is altered primarily due to the re-
emergence of S24-7, a specific bacterial taxonomic family within the Bacteroidetes phylum. 
Despite this alteration, fecal ammonia levels remain diminished and without consequence to the 
metabolic physiology of the host on a LPD. 
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Results 
LPD impacts host physiology and nitrogen metabolism but modestly alters the composition of the 
gut microbiota 
We first set out to investigate the effects of a LPD on both the murine host and the gut 
microbiota. Fifteen adult female C57BL6J mice were placed on an open source irradiated purified 
rodent diet containing normal amount of dietary protein at 21% by kilocalories (AIN-76A), 
henceforth referred to as normal protein diet (NPD, Sup. Table 5.1) for one week upon arrival into 
the University of Pennsylvania SPF vivarium. Subsequently, ten of the 15 mice were switched to 
an irradiated low protein diet (LPD, Sup. Table 5.1) formulated using AIN-76A as the base that 
contains 3% protein by kilocalories. The LPD was made isocaloric by proportionally increasing 
carbohydrate content while keeping fat content unchanged. The remaining 5 mice continued to be 
fed the NPD. We monitored physiological changes in these mice using body weight and food 
intake measurements as well as body composition determination via nuclear magnetic resonance 
(NMR) imaging. We found that compared to NPD-fed mice, LPD-fed mice exhibited poor weight 
gain despite equivalent caloric consumption (Figure 5.1A). LPD-fed mice also demonstrated 
increased fat mass and decreased lean mass (Figure 5.1B and 5.1C). Corresponding to a 
reduction in serum urea level compared to NPD-fed mice (Figure 5.1D), LPD-fed mice exhibited 
significant reductions in fecal urea and fecal ammonia levels after ten weeks on the LPD (Figure 
5.1E and 5.1F). These results are consistent with the fundamental role that dietary protein plays 
in host nitrogen balance. Reduction in dietary protein may have an effect on the gut microbiota by 
reducing the delivery of urea to the colonic environment leading to the reduction in fecal ammonia 
levels. 
16S tagged sequencing (1045 to 5305 reads per sample, median = 3448 reads) revealed 
modest yet distinct differences in the composition of the fecal microbiota in mice after placement 
on the LPD. These difference can be visualized in principal coordinates analysis of weighted 
(Figure 5.2A) and unweighted (Figure 5.2B) UniFrac distance. The LPD led to a significant 
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increase in the diversity of the gut microbial community as assessed by the Shannon diversity 
index (Figure 5.2C and Sup. Figure 5.1). The LPD also led to significant increases in the relative 
abundance of Mollicutes and Coriobacteria and a decrease in the Firmicutes classes 
Erysipelotrichi and Clostridia (Figure 5.2D and 5.2E). 
LPD has no effect on the initial engraftment of ASF into the host microbiota 
We have previously shown that there is a reduction in gut bacterial biomass upon 
treatment of mice with oral antibiotics (vancomycin and neomycin) and PEG, thus permitting the 
engraftment of ASF upon inoculation by oral gavage [12]. However, the effect of a LPD on the 
engraftment of ASF into the gut of a prepared host remains unknown. After preparation with 
antibiotics and PEG, we orally inoculated five of the LPD-fed mice with ASF (herein referred to as 
“ASF-transplanted”). As a control group, we transplanted the other five LPD-fed mice using feces 
from conventionally-reared donor mice (herein referred to “NF-transplanted,” for Normal Feces). 
Using 16S rRNA tagged sequencing, we tracked taxonomic alterations in the gut microbiota over 
time. We found that NF-transplanted mice exhibited minimal change in the composition of their 
gut microbiota (Sup. Figure 5.2). However, the gut microbiota of ASF-transplanted mice 
underwent a shift in composition in a similar fashion to that previously observed in NPD-fed mice 
transplanted with ASF [12], as shown in Figure 5.3A and 5.3B. In particular, the shifts along PC1 
in both cohorts of mice represent changes due to the initial ASF inoculum (compare days 0 to 14 
in both groups), whereas differences between the two cohorts of mice along PC2 may represent 
the effect of diet. These findings suggest that a LPD does not affect the initial engraftment of ASF 
into the host microbiota.  
Diet affects the resilience of the gut microbiota engineered by inoculation with ASF 
By tracking the composition of mice inoculated with ASF, we determined the effect of a 
LPD on the ability of ASF to engineer a different microbiota composition. In the setting of a NPD, 
we previously observed that ASF transplantation led to the development of a new steady state 
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community after one month composed of both ASF and the return of selected taxa of the 
Firmicutes phylum, but no non-ASF Bacteroidetes [12]. We proposed that Parabacteroides 
ASF519, the dominant taxon in ASF in feces, may have prevented the return of other 
Bacteroidetes taxa by competitive niche exclusion. Tracking compositional changes in the gut 
microbiota over time, we found that in the setting of the LPD, the gut microbiota engineered by 
ASF inoculation developed into an alternative rich community with diversity similar to that on the 
NPD (Figure 5.3C). However, ASF519 did not suppress the return of other Bacteroidetes. 
Instead, Bacteroidetes S24-7, a poorly classified yet common bacterial taxon in the commensal 
murine gut microbiota [22, 23], returned after ASF transplantation and reached an equilibrium 
state with ASF519 (Figure 5.4 and Sup. Figure 5.3). We plotted the progression of the 
transplanted ASF community over time. We found that ASF reached a new steady state in the 
setting of the LPD at around 4 weeks after transplantation, similar to what we previously observed 
in the setting of the NPD [12] (Figure 5.3A and 5.3B). However, this steady state more closely 
resembled the endogenous microbiota, likely as a result of the return of S24-7 on the LPD (best 
observed in Figure 5.3A along PC1 – compare the solid to dotted grey line). Overall, these 
findings suggest that ability of ASF lineages to compete is reduced in the presence of a LPD. 
The ASF-engineered gut microbiota lowers fecal ammonia more effectively than LPD alone 
We have previously shown that ASF transplantation durably reduces fecal ammonia by 
decreasing fecal urease activity [12]. Since a LPD itself mainly reduces fecal ammonia levels by 
decreasing the delivery of urea to the colon (Figure 5.1E and 5.1F), we sought to determine 
whether the ASF-engineered microbiota would be able to reduce fecal ammonia levels below 
those achieved by a LPD alone. We measured fecal urea and fecal ammonia levels in mice at 
baseline on the NPD, after ten weeks on the LPD, and compared ASF and NF transplantation on 
the LPD. As shown in Figure 5.5A, after the initial reduction in fecal ammonia levels induced by 
the LPD, ASF transplantation reduced fecal ammonia further than did NF transplantation. The 
ability of the ASF-engineered microbiota to lower fecal ammonia levels below those achieved by 
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the LPD alone is likely due to the reduction in fecal urease activity since there was no difference 
in fecal urea levels after NF and ASF transplantation (Figure 5.5B). These results indicate that the 
functionality of the ASF-engineered gut microbiota is not significantly altered in the setting of a 
LPD despite alterations in its composition. 
The low fecal urease and fecal ammonia-producing microbiota engineered by ASF inoculation 
does not exacerbate host metabolic dysfunction induced by LPD 
Urea is a nitrogenous waste product, but it is thought to contribute to host nutrition via 
urea nitrogen recycling by intestinal bacterial urease in both ruminants and non-ruminants, 
leading to microbial and/or host synthesis of peptides, amino acids, and other small molecules 
[14]. We asked whether this role of urea may become important for host physiology in the setting 
of a LPD, where systemic nitrogen is reduced. After transplanting the above cohort of mice with 
ASF or NF, we continued to monitor their body weight, food intake, and survival. Remarkably, 
despite the absence of colonic urea nitrogen recycling, ASF-transplanted mice did not differ 
significantly from NF-transplanted mice (Figure 5.5C, 5.5D, and Sup. Figure 5.4). Thus, in the 
setting of a LPD, ASF transplantation does not lead to significant detrimental changes to host 
physiology and metabolism. 
Discussion 
The success of FMT in the treatment of recurrent Clostridium difficile infections provides 
proof of concept that the gut microbiota can be a target for the treatment of disease in humans. 
The use of fecal transfer will likely be replaced by the use of defined microbial consortia with 
specific biological properties. As proof of concept, we have shown in murine models that a 
defined consortium of eight bacteria, known as Altered Schaedler Flora (ASF), can be used to 
engineer the gut microbiota with altered functionality, namely a reduction in fecal urease activity 
and ammonia production [12]. Critical to the success of this strategy is the substantial reduction in 
the biomass of the baseline microbiota to provide a niche into which the bacterial inoculum can 
engraft. 
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 An important consideration for engineering the gut microbiota is resilience to 
environmental stress. An optimally engineered microbiota would be a rich community that stays 
intact in the presence of environmental stress. Diet is an important environmental stressor on the 
gut microbiota that should be considered when engineering gut microbial communities. As one 
example, the low ammonia-producing microbiota engineered by ASF, which has functional 
durability for several months in mice fed an irradiated diet, shows reduced resilience when the 
mice are fed a non-irradiated diet [12]. We chose to study the impact of dietary protein on the 
resilience of the ASF-engineered microbiota for several reasons: 1) Dietary protein has been 
shown to influence the composition of the gut microbiota in gnotobiotic mice [24]; 2) Protein 
consumption regulates the production of hepatic urea that may affect colonic urea delivery to the 
gut microbiota [14, 25]; 3) Protein-restricted diets are an important therapeutic modality for 
patients with hyperammonemic inborn errors of metabolism [20, 26]. 
Unlike the modulation of fat and fiber in mice, which have been shown to have a strong 
effect on the composition of the murine gut microbiota [1, 24], we show that severe restriction of 
dietary protein had a modest effect. Within the Firmicutes phylum the Clostridia and 
Erysipelotrichi classes decreased significantly on a LPD, consistent with the preference of taxa 
within Firmicutes, particularly Clostridia species, to metabolize amino acids and peptides [27, 28]. 
Alternatively, since we show that a LPD reduces serum urea levels with reduced delivery to the 
colon resulting in lower fecal ammonia levels, an alteration in nitrogen flux via ammonia into the 
gut microbiota [29, 30] may also have an effect on the composition of the bacterial microbiota.  
Since we balanced protein with carbohydrate in the composition of the purified rodent 
diet, it is difficult to ascertain if the differences in the composition of the gut microbiota are due 
primarily to alterations in protein or in carbohydrate. We found that two bacterial phyla present at 
low abundances increased significantly on a LPD. Specifically, the classes Mollicutes 
(Tenericutes phylum) and Coriobacteria (Actinobacteria phylum) increased on a LPD. Previous 
work has shown that Mollicutes proliferated on a typical Western diet characterized by high-
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fat/high-sugar content, likely because of their ability to import and process simple sugars [31]. 
Thus, an increase in the abundance of Mollicutes that we observed on a LPD could be due to the 
increase in carbohydrate content rather than the reduction in protein content. Another study also 
showed that gut colonization by Actinobacteria and Tenericutes was strongly correlated with 
decreased hepatic levels of glycogen and glucose [32], further suggesting the interplay between 
the host and these two phyla may be closely related to carbohydrate metabolism. 
 Despite the effect of a LPD on the composition of the gut microbiota at baseline, this did 
not have an effect on the initial engraftment of ASF at 2 weeks, demonstrating that the use of 
antibiotics and PEG effectively prepared the environment of the gut for inoculation by a minimal 
defined bacterial consortium. Subsequently, development of the resultant engineered microbiota, 
determined by emergence of various bacterial taxa in addition to ASF, was distinctly different in 
mice fed a NPD versus a LPD. On a NPD, we previously showed that the dominant taxon 
Parabacteroides (ASF519) was able to exclude the entire Bacteroidetes phylum yet permit the 
reappearance of specific taxa belonging to the Firmicutes phylum. The observation that bacterial 
lineages with similar phylogeny exhibit competitive niche exclusion has been demonstrated in the 
Bacteroides genus where successful competition for carbohydrate substrates plays an important 
role [33]. By contrast, on a LPD, the resultant engineered microbiota appears to be more similar 
to baseline primarily due to the reemergence of a single bacterial taxon belonging to the 
Bacteroides family, S24-7. 
 S24-7 has been previously recognized as a dominant taxonomic group in the murine 
microbiota. It was first characterized by Salzman et al., who referred to the taxon as “mouse 
intestinal bacteria” [22]. The S24-7 taxon is phylogenetically distinct from other named genera in 
the order Bacteroidales. The taxon has been reported as altered in several recent mouse studies: 
it was increased in proportion following partial hepatectomy [34], associated with co-infection by 
Hymenolepis spp. [35], and decreased in proportion following antibiotic treatment for parenteral 
nutrition-associated liver injury [36]. However, to our knowledge, no study has previously 
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characterized competition between S24-7 and other Bacteroidetes species in mice. The S24-7 
taxon is typically encountered at very low (<1%) abundance in fecal samples from human 
populations. However, one study of a previously uncontacted Amerindian population reported the 
taxon to be enriched in isolated Yanomami Amerindians relative to Guahibo Amerindian, 
Malawian, and U.S. subjects [37]. The average abundance of the taxon in Yanomami 
Amerindians was reported to be nearly 5% of total bacteria, suggesting a potential role for S24-7 
in the human gut. 
 Upon reduction of bacterial biomass through a combination of antibiotics and 
polyethylene glycol (PEG), S24-7 is no longer detectable and shows no return over time after 
mice have been inoculated with ASF. Since both Paracteroides (ASF519) and S24-7 are closely 
related within the Bacteroidetes phylum, we speculate that S24-7 may be co-excluded from the 
luminal gut environment by ASF519 through competitive niche exclusion, a mechanism that has 
been hypothesized as the basis for the inversely-related proportions of Bacteroides and 
Prevotella in the human gut microbiota [2, 38], a predominant feature of “enterotypes” [39]. From 
a mechanistic standpoint, the basis of competitive niche exclusion may involve the competition of 
metabolic substrates as has been demonstrated for Bacteroides species in a reductionist model 
system [33]. Since S24-7 reappears and co-exists at approximately equal levels with ASF519 in 
LPD-fed mice, the alteration of substrate availability via diet may have altered the luminal 
environment of the gut that reduces the need for competition between these two taxa. For 
example, a LPD may have altered the balance of nitrogen flux into the gut microbiota via the 
uptake of ammonia. Indeed, despite the return of S24-7 and the similarities between the 
composition of a gut microbiota of a conventionally-housed mouse and the ASF-engineered 
community established in LPD-fed mice, fecal ammonia levels remained much lower in ASF-
transplanted mice that those transplanted with normal feces. This suggests that S24-7 may be 
urease negative. Further elucidation of such mechanism(s) will require genomic characterization 
of S24-7 along with an evaluation of its biological properties.   
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 The quantification of fecal ammonia was used to determine the impact of microbiota 
composition on the function of the community. Despite the modest alterations in the gut 
microbiota induced by the consumption of a LPD, there was a significant reduction in fecal 
ammonia levels reflecting the reduced abundance of urea substrate available for hydrolysis by 
the gut microbiota. This observation emphasizes the notion that diet may have an indirect impact 
on the gut microbiota by alteration of the host similar to the outgrowth of a pathobiont due to the 
enhanced production of sulfated bile acids in mice fed milk fat [40]. Importantly, engineering of 
the gut microbiota using ASF led to a reduction in fecal ammonia levels significantly greater than 
that observed on a LPD.  
 Since ammonia, produced by the gut microbiota via urease activity, is absorbed by the 
host where it can be used for amino acid synthesis, it has been hypothesized that this form of 
nitrogen recycling may be important for host health especially under conditions of limited protein 
intake [14, 41]. This might be a significant limitation of a strategy focused on reducing gut 
microbiota ammonia production for the treatment of hyperammonemia and hepatic 
encephalopathy [12]. Although LPD-fed mice did not exhibit growth, as would be expected, ASF 
transplantation with subsequent robust reduction of fecal ammonia levels did not lead to any 
effects on food intake, growth, or mortality relative to LPD-fed mice transplanted with normal 
feces who had much higher levels of fecal ammonia. Since patients with hyperammonemic inborn 
errors of metabolism are placed on a LPD to prevent metabolic crises, our observations provide 
preliminary evidence that the engineering of gut microbiota to reduce fecal ammonia production 
may be well tolerated in this patient population. However, additional safety studies are needed. 
 In summary, we show that diet has a significant effect on the ability of a defined microbial 
consortium to engineer the composition of the gut microbiota. Specifically, LPD alters the co-
exclusion of two dominant taxa within the Bacteroidetes phylum. Given the alterations in the 
syntropic host-microbiota interactions in nitrogen flux that occur in the levels of urea delivery from 
the host to the gut microbiota, the reduced production of ammonia via bacterial urease, and the 
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uptake of ammonia by both the host and the gut microbiota, a LPD may be a particularly 
important environmental stressor that will impact upon the composition of an engineered 
microbiota. Nevertheless, the functionality of the engineered gut microbiota, as quantified by a 
reduction in fecal ammonia levels, remained intact. Together with the absence of detrimental 
effects on host physiology in the setting of a LPD, the reduction in fecal ammonia levels via 
engineering of the gut microbiota may be an effective therapeutic strategy for patients with 
hyperammonemic inborn errors of metabolism. 
Methods 
Animals  
C57B6J female mice 8 to 12 weeks old (The Jackson Laboratory) were used in this 
study. Fecal pellets collected from ASF-colonized CB17 SCID mice (Taconic) served as the 
source of the ASF innoculum whereas conventionally-colonized C57B6J mice (The Jackson 
Laboratory) served as the source of the normal flora (NF) innoculum used in the FMT procedures 
as previously described [12]. Fecal homogenates were prepared by diluting 0.1 g feces 10-fold in 
PBS. Mice were prepared for FMT by oral delivery of antibiotics in drinking water (1.125 g 
aspartame, 0.15 g vancomycin, and 0.3 g neomycin in 300 mL sterile water) for 72 hours. During 
the final 12 hours, the water supply was exchanged with a 10% PEG solution (Merck), and the 
mice were fasted. Mice were then inoculated daily with fecal homogenates by oral gavage for 7 
days. All mice were housed five per cage in a conventional specific-pathogen free (SPF) facility 
(and transferred from one conventional facility to another conventional facility within the University 
of Pennsylvania 10 weeks after the start of experiment for NMR imaging) and fed irradiated AIN-
76A (Research Diets D10001, 21% protein by kilocalories – NPD, see Sup. Table 5.1). After one 
week, ten mice were switched to irradiated AIN-76A with lower protein content (Research Diets 
D08092201, 3% protein by kilocalories – LPD, see Sup. Table 5.1). Fecal pellets were collected 
at baseline on NPD, 10 weeks after placement on LPD, 2 weeks after  FMT (15 weeks on LPD), 4 
weeks after FMT (17 weeks on LPD), and 10 weeks after FMT (23 weeks on LPD) for bacterial 
 101 
taxonomic and biochemical analyses. Fecal pellets were collected in 1.5 mL microcentrifuge 
tubes (Sigma-Aldrich) and immediately placed on dry ice then stored in -80°C freezer until time of 
analysis. Body composition was determined using NMR imaging via the Mouse Phenotyping, 
Physiology and Metabolism Core at the University of Pennsylvania. All animal studies were 
performed with the approval of the Institutional Animal Care and Use Committee of the University 
of Pennsylvania (Protocol Number: 803408). 
16S V1-V2 sequencing 
DNA was isolated from stool as previously described [2, 42]. 100 ng of DNA was 
amplified with barcoded primers annealing to the V1-V2 region of the 16S rRNA gene (forward 
primer, 5′-AGAGTTTGATCCTGGCTCAG-3′; reverse primer, 5′-CTGCTGCCTYCCGTA-3′; [43, 
44] using AccuPrime Taq DNA Polymerase System with Buffer 2 (Life Technologies). PCR 
reactions were performed on a thermocycler using the following conditions: initiation at 95°C for 5 
min followed by 20 cycles of 95°C × 30 s, 56°C × 30 s, and 72°C × 1 min 30 s, then a final 
extension step at 72°C for 8 min. The amplicons from each DNA sample, which was amplified in 
quadruplicate, were pooled and purified with Agencourt AMPure XP beads (Beckman Coulter) 
following the manufacturer’s instructions. Purified DNA samples were then sequenced using the 
454/Roche GS FLX Titanium chemistry (454 Life Sciences). 
16S rRNA gene sequence analysis 
16S rRNA gene sequence data was processed with QIIME v 1.8.0 [45] using default 
parameters. Sequences were clustered into operational taxonomic units (OTUs) at 97% similarity 
and then assigned Greengenes taxonomy [46] using the uclust consensus taxonomy classifier. 
Sequences were aligned using PyNAST [47] and a phylogenetic tree was constructed using 
FastTree [48]. Weighted and unweighted UniFrac [49] distances were calculated for each pair of 
samples for assessment of community similarity and generation of principal coordinate analysis 
(PCoA) plots.  Statistical analyses for bacterial abundance difference was performed using non-
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parametric Wilcoxon test, and p-values were corrected for multiple comparisons using the 
Benjamini and Hochberg procedure. 
Measurement of fecal ammonia 
Fecal ammonia concentrations were determined using an Ammonia Assay Kit (ab83360, 
Abcam, Cambridge, MA). Fecal pellets were suspended in the assay buffer provided at a 
concentration of 1 mg/10 uL, homogenized, and centrifuged at 13,000 x g for 10 minutes at room 
temperature to remove insoluble material. Ammonia concentration was then determined 
according to the kit protocol. 
Measurement of serum and fecal urea  
Urea concentrations were determined using the QuantiChrom™ Urea Assay Kit (DIUR-
500, Bioassay Systems, Hayward, CA). Serum samples were assayed directly. Fecal pellets were 
suspended in ddH2O at a concentration of 1 mg/10uL, homogenized, and centrifuged at 2,500 x g 
for 10 minutes at room temperature to remove insoluble material. Urea concentration was then 
determined according to the kit protocol. 
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Figures 
Figure 5.1. Changes in murine physiology and nitrogen metabolism on a LPD. Differences 
in (A) body weight (n=5 in NPD group, n=10 in LPD group), (B) % fat mass, (C) % lean mass, and 
(D) serum urea levels between NPD-fed and LPD-fed mice. (E) Fecal urea and (F) fecal ammonia 
levels at baseline on the NPD and after placement on the LPD. Values represent mean ± SEM. 
Statistical significance in body weight determined by two-way ANOVA with repeated measures; 
statistical significance in other parameters determined by paired and unpaired two-tailed 
Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.2. Effect of a LPD on the composition of the gut microbiota. Principal coordinates 
analysis (PCoA) ordination of mice before and after placement on the LPD for 10 weeks. 
Changes in community membership were analyzed using (A) weighted and (B) unweighted 
Unifrac. (C) The interquartile range of Shannon diversity values is shown for mice on the NPD 
who were later put on the LPD (Wilcoxon rank sum test p-value = 0.0001299). (D) Heatmap 
showing the relative abundance of bacterial lineages over time in mice who were on the NPD at 
baseline and then after ten weeks on the LPD. Rows indicate bacterial lineages annotated at the 
class taxonomic level on the left. The color key on the right of the figure indicates relative 
abundance. Columns summarize the sequencing results from individual fecal specimens. Each 
column represents a different mouse. The columns are grouped by diet. (E) Bacterial lineages 
that change on the LPD. Four bacterial classes significantly differed between the NPD and LPD 
(FDR-corrected Wilcoxon test p-value < 0.05). Relative abundance of each class in both diet 
groups is shown. Box and whiskers show the interquartile range; black circles mark the outlier 
samples. 
 
 
  
PC2 (17.8%)
PC1 (43.1%)
Weighted Unifrac Ordination
PC2 (15.3%)
PC1 (21.6%)
Unweighted Unifrac Ordination
10 weeks on LPD
Baseline on NPD
A B
D
E
Pr
op
or
tio
n
Actinobacteria Coriobacteriia
0.00
0.01
0.02
0.03
q=0.027
Tenericutes Mollicutes
0.000
0.005
0.010
0.015
0.020
q=0.002
Firmicutes Erysipelotrichi
0.00
0.01
0.02
0.03
0.04
0.05 q=0.009
10 weeks on LPDBaseline on NPD
Actinobacteria Coriobacteriia
Other Bacteria
Bacteroidetes Other
Bacteroidetes Bacteroidia
Firmicutes Other
Firmicutes Bacilli
Firmicutes Clostridia
Firmicutes Erysipelotrichi
Proteobacteria Alphaproteobacteria
Tenericutes Mollicutes 0
0.2
0.4
0.6
0.8
1
Firmicutes Clostridia
0.60
0.65
0.70
0.75
q=0.027
C
Sh
an
no
n
Di
ve
rs
ity
p=0.00013
Baseline
on
NPD
10 weeks
on
LPD
3.8
4.0
4.2
Baseline
on
NPD
10 weeks
on
LPD
Baseline
on
NPD
10 weeks
on
LPD
 105 
Figure 5.3. Effect of a LPD on the initial engraftment of ASF and subsequent resilience 
over time. Principal coordinates analysis (PCoA) ordination of mice after transplantation with 
ASF. Changes in community membership were analyzed using (A) weighted and (B) unweighted 
Unifrac. Dietary groups are color coded as indicated with the shades of colors indicating 
progression in time. Day 0 samples have gray circles around them (solid for NPD, dashed for 
LPD). The arrows were added to help visualize the progression of time after ASF transplantation. 
(C) The interquartile range of Shannon diversity values are shown for mice on the NPD and LPD 
inoculated with either ASF or Normal Feces (NF). Black circles mark the outlier samples.  
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Figure 5.4. S24-7 returns after ASF transplantation into mice on a LPD but not on a NPD. 
(A) Relative abundance of bacterial taxa are shown. Each column represents a single sample of a 
pre-treated, ASF-inoculated mice on the LPD (LPD + ASF). Progression of inoculation is shown 
across multiple days post inoculation with ASF.  Relative abundance of (B) Parabacteroides 
(including ASF 519) and (C) S24-7. Box and whiskers show the interquartile range; black circles 
mark the outlier samples. 
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Figure 5.5. ASF transplantation alters colonic urea nitrogen recycling without significantly 
affecting host physiology. (A) ASF transplantation reduces fecal ammonia below the level 
achieved by the LPD alone (n=4-5 per group, *p<0.05 compared to baseline, **p<0.01 compared 
to 10 weeks on the LPD). (B) No difference in fecal urea level between ASF- and NF-transplanted 
mice (n=2-5 per group, *p<0.05 compared to baseline, **p<0.01 compared to baseline). No 
difference in (C) body weight or (D) food intake between ASF- and NF-transplanted mice (n=5 per 
group). Values represent mean ± SEM. Significance determined by two-tailed Student’s t-test. 
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Supplemental Information 
Sup. Table 5.1. Components of normal protein and low protein diets.  
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Sup. Figure 5.1. Diversity in each mouse after a LPD. Shannon diversity is shown for all ten 
mice while on the NPD (blue) and after ten weeks on the LPD (salmon).  
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Sup. Figure 5.2. Principal coordinates analysis ordination of mice on the LPD after 
transplantation with ASF or NF. Changes in community membership were analyzed using (A) 
weighted and (B) unweighted Unifrac. 
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Sup. Figure 5.3. Relative abundance of bacterial taxa after ASF transplantation. Each bar 
represents a single sample. Samples represent pre-treated ASF-inoculated mice on the NPD 
(NPD + ASF). Progression is shown across multiple days post-inoculation with ASF.   
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Sup. Figure 5.4. Murine mortality on a LPD. Kaplan Meier curve showing no significant 
difference in survival between ASF- and NF-transplanted mice on the LPD (n=5 per group at start 
of experiment). 
 
  
0 50 100 150 200
0
50
100
Days
Pe
rc
en
tS
ur
vi
va
l LPD + ASF
LPD + NF
 117 
CHAPTER 6: Transfer of Viral Communities between Human Individuals during 
Fecal Microbial Transplantation. 
The contents of this chapter have been published as:  
Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister E, Luna R, Versalovic J, 
Kellermayer R, Bushman F. 2016. Transfer of Viral Communities between Human 
Individuals during Fecal Microbial Transplantation. mBio (PMID: 27025251). 
 
Abstract 
Fecal microbiota transplantation (FMT) is a highly effective treatment for refractory Clostridium 
difficile infections. However, concerns persist about unwanted co-transfer of pathogenic microbes 
such as viruses, which has not previously been investigated. Here we study FMT from a single, 
healthy human donor to three pediatric ulcerative colitis patients, each of whom received a course 
of 22 to 30 FMT treatments. Viral particles were purified from donor and recipient stool samples 
and sequenced; the reads were then assembled into contigs corresponding to viral genomes or 
partial genomes. Transfer of selected viruses was confirmed by quantitative PCR. Viral contigs 
present in the donor could be readily detected in recipients, with up to 32 different donor viral 
contigs appearing in a recipient sample. Reassuringly, none of these were viruses are known to 
replicate on human cells. Instead, viral contigs either scored as bacteriophage or could not be 
attributed taxonomically, suggestive of unstudied phage. The two most frequently transferred 
gene types were associated with temperate phage replication. Also, Siphoviridae, the group of 
typically temperate phages that includes phage lambda, were found to be transferred with 
significantly greater efficiency than other groups. Based on these findings, we propose that the 
temperate phage replication style may promote efficient phage transfer between human 
individuals. In summary, we documented transfer of multiple viral lineages between human 
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individuals through FMT, but in this case series none were from viral groups known to infect 
human cells. 
Introduction  
Fecal microbiota transplantation (FMT) has been used to treat relapsing Clostridium 
difficile infection with great success and shows promise for other indications (1, 2). However, 
many pathogenic human viruses are known to be transmitted via the fecal-oral route, and viral 
transfer accompanying FMT has not been studied previously. Here we investigate viral transfer 
during FMT using model-independent metagenomic sequencing.  
Introduction of single viruses into humans has been closely studied, but the transfer of 
populations of viruses is much less well-understood. Multiple viruses are commonly found as co-
infections in humans, though it is usually unknown whether acquisition of these viruses was 
sequential or simultaneous. Careful tracking of transmitted founder viruses during HIV and HCV 
transmission has revealed examples of probable simultaneous transfer of multiple lineages (3, 4). 
HIV and HCV commonly co-occur and may be acquired simultaneously during intravenous drug 
use (5). For the case of satellite viruses (e.g. Hepatitis B and its satellite virus Hepatitis D) the two 
are inferred to commonly infect together because the satellite depends on its helper for replication 
(6). Multiple viruses that replicate in human cells may be transferred together during organ 
transplantation (7). For bacterial viruses, simultaneous acquisition of multiple lineages has rarely 
been investigated. 
The human fecal virome is immense in the numbers of viruses present—comparable to 
the number of bacteria, which is 1011 per gram of feces—and the number of different types. Gut 
bacteriophages are so numerous and diverse that sequence databases contain only a small 
fraction of the global population (8-14). Thus, simply sequencing total DNA from stool and 
aligning to database genomes generally misses most of the bacteriophage sequences present, 
necessitating specialized methods. 
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In this study, we investigated the transfer of viral communities between humans through 
FMT and characterized features associated with particularly efficient transmission. We took 
advantage of a case series where feces from a single donor were used to treat three children with 
ulcerative colitis (UC) (15). These subjects received a particularly intensive procedure, which 
consisted of 22 to 30 FMT treatments per subject delivered by colonoscopy or enema during a 6 
to12 week period. We performed metagenomic analysis of viral particle fractions purified from 
fecal samples from the donor, the donor product, and recipients before, during, and after 
transplantation. To track viral transfer, we assembled contigs representing viral genomes and 
monitored their abundances through the transplantation process. All recipients were detectably 
colonized by multiple donor viruses, documenting transfer of whole viral populations. None of the 
transferred viruses were from groups known to replicate on human cells, supporting the safety of 
the FMT procedure in this application. 
Results 
Subjects studied 
Three pediatric UC patients receiving immunotherapy regimens were switched to 
receiving a course of 22 to 30 FMT treatments via colonoscopy or enema during a 6 to12 week 
period (Figure 6.1A) (15). Donor stool specimens were from a single, healthy, 37-year-old male. 
FMT in all three patients was associated with a symptom-free period of at least 4 weeks, 
supporting the temporary withdrawal of immunotherapy (no treatment other than mesalamine). 
Treatment was associated with endoscopic and histologic remission for at least 2 weeks after the 
last FMT. All three subjects eventually relapsed and resumed therapy with immunomodulators.  
Analysis of transfer of bacterial lineages 
Bacterial microbiota composition was investigated by purifying DNA from stool and 
sequencing a segment of the 16S rRNA gene as described (15). The donor samples contained 
high levels of Bacteroides and lower levels of Firmicutes such as Dialister and Subdoligranulum. 
 120 
Prior to FMT, the three recipients harbored communities dominated by Subdoligranulum, 
Prevotella, and Bacteroides respectively. During FMT, Bacteroides dominated in all three 
recipients (Figure 6.1B). After completion of the FMT treatment, Bacteriodes persisted, but 
Firmicutes lineages also increased in abundance in recipients 2 and 3. Global community 
analysis showed that for all three recipients, microbial communities during FMT became 
detectably (though modestly) closer to that of the donor. After FMT, all three recipients’ microbial 
communities increased in diversity (Sup. Figure 6.1), suggestive of acquisition of healthier 
microbiota.  
Composition of the fecal virome in donors and recipients 
To study viral transfer, virus-like particles (VLPs) were purified from 18 samples. We 
compared four donor samples of two types: two were crude stool samples and the other two were 
processed to generate the liquid product used for FMT. Recipient samples were taken prior to 
FMT, during the FMT intervention (after the 13th FMT treatment), and after the FMT was 
completed. The five control samples were 1) a stool sample from a healthy 25-year-old male, 2) 
two stool samples from pediatric Crohn’s Disease patients on immunotherapy but not receiving 
FMT, and 3) two buffer only negative control samples. The first three control samples were from 
well-studied subjects and serve as positive controls. The two pediatric Crohn’s Disease patients 
were selected because a previous metagenomic study had shown them to harbor Anelloviruses 
(Torque Teno virus) and Parvoviruses (Human Bocavirus) (16). The two buffer controls were 
included to document contamination from reagents and environmental admixture.  
VLPs were purified from the 18 samples, then DNA isolated from the particles. VLP DNA 
was amplified using multiple displacement amplification (MDA) and the product sequenced using 
Illumina technology. Quantitative PCR for 16S was used to assay contaminating bacterial DNA, 
documenting only low level carry over (Sup. Table 1). Here we only investigate DNA viruses. 
RNA viruses are less abundant in stool than DNA viruses, and previous studies from us and 
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others suggest that many of the RNA viruses present in stool are transient plant RNA viruses 
derived from food ((17) and unpublished). 
At least one million reads were acquired from each fecal sample (Sup. Table 2), allowing 
detailed investigation of the viral populations. Low quality reads were filtered out, as were reads 
mapping to the human genome (hg18) and phage phiX174 (the latter is added to sequencing 
mixtures for technical reasons). Reads were aligned to a curated viral database (18) using a 
permissive alignment threshold (BLAST e-value 10-3). After filtering out low abundance negative 
control samples (<50,000 reads) plots of the proportions of the most abundant taxa are shown 
(Figure 6.1C). The majority of reads did not align to reference database sequences (an average 
of 17.9% of reads returned significant matches).  
Of the reads that did align, the most common assignments were Microviridae, which are 
non-enveloped, single stranded DNA phages from the family including phiX174, and 
Caudovirales, which is a broad family including all of the tailed phages. Of the two controls with 
known animal cell viruses, Anelloviruses were recovered efficiently, and Bocavirus less efficiently. 
The MDA step is known to amplify single stranded circular DNA particularly efficiently, likely 
explaining the abundance of Anelloviruses and Microviridae, both of which have small single 
stranded circular DNA genomes. 
To examine the VLP genomes in our samples more fully, reads were assembled into 
contigs using deBruijn graph assembly (19) and overlap consensus methods (20). A total of 3634 
contigs were built from the four donor samples (Sup. Table 3). Of these, 261 were greater than 
3000 base pairs in length (mean length 8161 bp and maximum length 65335 bp). For the 
recipients, a total of 486, 1177, and 1936 contigs were built from each pre-FMT sample; of these 
contigs, 38, 138, and 127 contigs were greater than 3000 base pairs (Sup. Table 4). These 
contigs were assessed for length, circularity, and number of open reading frames (ORFs). Nine of 
the 261 contigs were circular, suggesting that we had sequenced the entire viral genome (Sup. 
Figure 6.2). With one exception, these clustered at specific lengths suggestive of Anelloviruses 
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(~3000 bp), Microviridae (~5000-6000 bp), and Siphoviridae (typically >30000 bp). One circular 
contig (8662 bp) was annotated as Podoviridae (typically >40000 bp), suggesting it may have 
assembled as a circle due to the presence of a repeated sequence. Linear contigs are either 
complete linear genomes or genome fragments. 
Proteins encoded in the gut virome 
To catalog the genes present, open reading frames (ORFs) were predicted, conceptually 
translated and aligned to several protein databases (19, 21, 22), including one composed of 
conserved protein domains (from the Conserved Domains Database (CDD)) known to be 
associated with viruses (12, 14). A total of 3,321 ORFs were predicted. Protein types found in the 
donor and in each recipient pre-FMT are summarized in Figure 6.1D. Only an average of 7.3% of 
proteins were annotated, which emphasizes the size of the pool of uncharacterized 
bacteriophage genes. Prominent CDD types were associated with phage capsids, tails, portals, 
terminases and other structural components. Additional annotations were associated with effector 
proteins including bacteriocin, beta-lactamase, reverse transcriptase, and restriction modification.  
Contigs of length >3000 bp had on average 6 ORFs, allowing us to use gene family 
membership to annotate the probable viral family of origin. We found that on average each contig 
had two ORFs matching a viral genome (BLAST e-value 10-5). The majority of classified VLP 
genomes belonged to tailed phages (Caudovirales), which include Siphoviridae, Myoviridae, and 
Podoviridae. Microviridae were also prominent. In several cases single ORFs annotated as 
belonging to animal cell virus lineages (Poxviridae, Adenoviridae, and Herpesviridae), but multiple 
other ORFs on the same contig annotated as Caudovirales, so in these cases the Caudovirales 
attribution was retained, or multiple other ORFs were unclassified weakening the validity of an 
animal cell lineage. The two Crohn’s disease samples pre-selected for containing animal cell 
viruses returned contigs representing Anellovirus and Bocavirus as expected. 
Transfer of viral lineages with FMT 
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We then used the contigs of >3000 bp to investigate the transfer of phages during FMT 
(Figure 6.2, Sup. Figure 6.3). To score detection of a donor contig in a recipient, we required 
>50% coverage of the contig and alignment of at least 5 paired reads, where both reads in each 
pair showed high quality alignment to the target contig. We note that these criteria are 
conservative, so the numbers of contigs transferred represent minimal estimates. Comparing to 
recipient samples at the first time point after initiation of FMT, while FMT was ongoing, we 
detected 21, 42, and 16 donor contigs respectively. At the second time point, 5 to 13 weeks later 
and 2 to 4 weeks after the completion of the FMT treatment, we detected 5, 7 and 34 donor viral 
contigs, respectively. Sup. Figure 6.4 shows examples of sequence alignments of reads from 
recipients at time points following transfer onto contigs built from donor reads, illustrating high 
coverage. 
To confirm the transfer from the donor to recipients, we used quantitative PCR (qPCR) to 
analyze VLP DNA samples (Figure 6.3). As template we analyzed fecal VLP DNA specimens that 
were not subjected to MDA amplification, which is known to distort relative abundances. To 
confirm that some lineages transferred efficiently, we analyzed four VLP contigs from the donor 
that were detected in at least two different recipients. QPCR assays were designed for each of 
the four contigs (Sup. Table 5), and positive control DNAs were synthesized for use as copy 
number standards. We compared results for the four donor samples to the nine recipient samples 
(three patients, three time points each). We also tested the same positive controls used in the 
viral sequencing analysis, specifically stool VLP DNA from a healthy 25-year-old male and two 
pediatric Crohn’s Disease patients. As a negative control, we used a commercial phage lambda 
DNA sample.  
All four qPCR assays detected the expected contigs in the donor samples and in at least 
two recipients. Levels were low in all controls. For contig 100-94 (annotating as Microviridae) and 
100-182 (Unattributed) donor contigs were detected after FMT in all three recipients (Figure 6.3A 
and 6.3B). For contigs 100-21 (Podoviridae) and 19 (Myoviridae), transfer was robust to subjects 
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2 and 3 (Figure 6.3C and 6.3D). The maximum copy numbers detected were in the range of 8-
15X103 copies per nanogram of VLP DNA. 
Viral features associated with efficient viral transfer 
We next investigated features of viral contigs associated with efficient transmission 
during stool transplantation. We first asked whether any inferred phage-encoded proteins could 
be identified that correlated with efficient transmission. Figure 6.4A shows the top two conserved 
domain families that correlated with frequency of transmission (p-values<0.05, odds ratio >4.2 
times more likely to be transferred). These transferred domains were found to be associated with 
the temperate replication style, in which phages form quiescent long-term associations with their 
bacterial hosts. The highest scoring family (pfam01051) is annotated as “initiator replication 
protein”. The best-studied member of this group is RepA protein of the temperate phage P1. 
RepA initiates DNA replication on the P1 genome, and related proteins also mediate replication of 
Herpes viruses. The second highest scoring family (pfam14659) is a domain from the lambda 
integrase family of integration proteins. Lambda integrase is well known to mediate integration 
during prophage formation. Thus both the analysis of preferential transfer of viral family types and 
transfer of viral genes indicated preferential transmission of temperate phage. 
We next asked whether any viral families were preferentially transferred by comparing 
frequencies in the donor versus recipient VLP populations. We focused the analysis on our most 
accurate detections, specifically the donor viral pool consisting of contigs >3000 bp. Comparison 
showed that Siphoviridae were significantly more likely to be transferred (p=0.0072 by Fisher’s 
exact test, Figure 6.4B). We repeated these tests by looking at Siphoviridae compared to all 
contigs and again found Siphoviridae to be significantly more likely to be transferred (p<0.0001 by 
Fisher’s exact test, Figure 6.4C). Siphoviridae include phage lambda, 434, and P22 and are 
known to include viruses with the capacity to integrate into host genomes (23).  
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To confirm transfer, we selected four contigs annotating as Siphoviridae and called as 
transferred, and designed qPCR assays to verify transfer. VLP DNA samples (not subjected to 
MDA) were tested, and contigs were detected in the donor and recipient as expected from the 
sequencing data (Figure 6.4 D-G). In all four cases, the transferred phage were detected in at 
least two out of the three recipients, indicating transfer to multiple individuals. 
Discussion 
Here we report transfer of gut viral communities associated with FMT. No viruses 
infecting human cells were detected in the donor, so reassuringly no transfer could be 
documented in recipients. Numerous recipient VLP sequence reads showed high quality 
alignments to donor VLP contigs, suggesting transfer with FMT. Many annotated as containing 
genes known to be phage encoded, supporting the inference that the VLP contigs corresponded 
to phage. From 5 to 34 transferred contigs could be detected in recipient samples. Simultaneous 
transfer of multiple viruses has rarely been documented in humans but was readily detected here, 
potentially associated with the large number of FMT treatments (22 to 30 per subject). Based on 
these observations, we propose that transfer of bacteriophage populations is a general 
characteristic of FMT. 
An alternative interpretation for our data could be that viruses were not transferred from 
donor to recipients, but instead were present in recipients initially below the level of detection. 
According to this view, viruses pre-existing in the recipient would have grown out after FMT, 
resulting in spurious appearance of transfer. We cannot completely rule this out, but several 
aspects of phage biology in the human gut support our interpretation. Bacteriophage populations 
in the intestines of healthy humans are known to show extreme differences among individuals (8-
14). However within an individual, populations show notable longitudinal stability, at least in 
healthy subjects (8, 10, 11). As a result, most VLP genomes are likely recognizable by their 
individual of origin. Thus, while it is possible that some new detections in recipients represent the 
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outgrowth of pre-existing viruses, or even de novo colonization, we expect that most recipient 
sequences resembling donor VLPs are genuinely derived from the donor stool product. 
Our most unexpected finding was that lysogeny is associated with efficient transfer by 
FMT. This was indicated first by the preferential transfer of the Siphoviridae, the group including 
the well-studied temperate phage lambda. Analysis of genes associated with transfer also made 
this point (Figure 6.4A). The most strongly associated gene encoded the RepA protein, important 
for replication of the temperate phage P1, and the second, encoded a domain of the lambda 
integrase proteins important for prophage formation. 
Based on our findings, we propose that the temperate phage replication style may have 
evolved in part to optimize phage transmission between environments. If bacteriophage must 
pass through hostile environments to reach locations favorable for replication, transportation as a 
prophage may promote dispersal. Transmission of gut viruses between human hosts potentially 
involves persistence outside the gut, likely representing a transmission barrier. Viruses 
transferred efficiently by the fecal-oral route are rarely enveloped, suggesting that tough physical 
properties may be needed to survive fecal-oral transmission. In feces, an enveloping membrane 
may be damaged by the detergent effects of bile salts or by drying after shedding in feces. 
Respiratory viruses, in contrast, are commonly spread on respiratory droplets and are often 
enveloped. Integration of prophage DNA into the bacterial genome may provide a protective 
vehicle supporting phage transmission despite exposure to feces or other hostile environmental 
pressures. Thus, we propose that the temperate phage replication style may in part have evolved 
to maximize survival during transmission. 
In summary, we presented a metagenomic survey of DNA viruses transferred during 
FMT. Numerous temperate phage were found to be transferred, but no viruses detected 
corresponded to pathogenic viruses that infect human cells. Methods for preparing and 
introducing feces into patients vary and may influence the likelihood of viral transmission, so 
additional characterization of viral transfer can help guide development of safest practices. 
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Methods 
Human subjects 
Human subjects and methods used for FMT have been described (15). As stated in the 
supplemental methods, fresh stool specimens from the healthy adult donor were aliquoted to ~50 
g aliquots. Cold sterile normal saline solution was added prior to homogenization in a strainer bag 
with 500-µm pore size (Seward Laboratory Systems Inc., Port Saint Lucie, FL) using the Smasher 
Laboratory Blender/Homogenizer (AES CHEMUNEX Inc., Cranbury, NJ). Both fresh stool 
samples and the homogenized stool preparations which were used for the  transplantation were 
analyzed in this study. Experiments were carried out under a protocol approved by the 
Institutional Review Board of Baylor College of Medicine (H-30591). 
DNA purification and sequencing 
Detailed methods are presented in the Supplemental Material and summarized here. 
Phage particles were purified from stool samples by suspension in SM buffer and filtration 
through a 0.22  µm filter (EMD, Millipore). The filtrate was concentrated using the 100  kDa 
molecular weight cutoff filter Centricon Plus 70 (Millipore), resuspended in 40  mL Buffer SM, and 
concentrated. The concentrate was treated with DNase I and RNase (Roche) at 37°C for 30  min 
to eliminate non-encapsulated nucleic acids, then the enzymes were deactivated at 65°C for 
15  min. Total phage DNA was extracted from particles using the QIAamp DNA Stool Kit (Qiagen). 
Extracted phage DNA was amplified using Illustra GenomiPhi V2 DNA Amplification Kit (GE 
Healthcare). Libraries were made using the Illumina Nextera XT Samples Prep Kit and quantified 
using the SYBR Fast Illumina Library Quantification Kit (Kapa Biosystems).  
Purified VLP DNAs were sequenced on three MiSeq runs (250 base per read, paired-end 
sequencing) according to manufacturer’s instructions (Illumina). Two negative control samples 
yielded 1242 and 36156 reads respectively. Contigs were built from the four donor samples and 
were annotated with open reading frames (ORFs), integrase genes, and viral family names based 
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on similarity to reference viral genomes. ORFs were also aligned to a database of conserved 
domain integrase genes (to assess potential temperate replication style), and also the Virulence 
Factor Database, Aclame database of mobile genetic elements, NCBI’s reference viral database, 
NCBI’s reference bacterial database, and NCBI’s nucleotide database to assess additional 
functional features (summarized in Supplemental Tables 3 and 4). Reads from all of the samples 
were mapped to contigs built from the four donor samples using Bowtie2 (24). Coverage metrics 
were calculated, including concordance rate between paired reads, average depth of coverage, 
and the percentage each contig was covered by reads.  
QPCR validation 
The qPCR for quantitating contigs was performed using FastSYBR Green Master Mix 
(Applied Biosystems). Primers are described in Supplemental Table 5. The ZeroBlunt TOPO 
Vector (ThermoFisher Scientific), containing the corresponding gBLOCK synthetic copy number 
control sequence, was linearized and used as a standard control.  
Quantification of 16S rRNA copy number was performed using the real-time TaqMan 
method with TaqMan® Environmental Master Mix 2.0 and primers as indicated in Supplemental 
Table 5. The ZeroBlunt TOPO Vector containing a near full-length clone of Escherichia coli 16S 
was linearized and used as a standard control. 
Statistical analysis 
Fisher’s exact test and odds ratios were used to assess significance of conserved 
domains or viral family transfer. 
Assessing contamination of phage DNA preparations with bacterial and human DNA 
Purities of the phage DNA preparations were assessed using qPCR to quantify bacterial 
16S rRNA gene copies (Sup. Table 6.1). Values ranged from 7 to 5021 16S rRNA gene copies/ng 
of purified phage DNA (average of 257 copies/ng). The contribution of bacterial DNA per 
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nanogram of purifed phage DNA could be estimated by assuming the average bacterial genome 
has 2 to 5 rRNA gene copies and is 2.5 to 5.5 Mb (25) total (MW 1.6 x 109 to 3.3x109), implying 
that implying that on average 1.0 nanogram of phage DNA was contaminated with 1.1 picograms 
of bacterial DNA. 
Human DNA contamination was also assayed by aligning sequence reads from the VLP 
DNA samples to the human genome. Most samples contained <1% human DNA; the highest 
value recorded was 4% (Sup. Table 2). We thus conclude that bacterial and human DNA were 
minor contributors to the VLP genomic DNA samples studied. 
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Figures 
Figure 6.1. Fecal microbiota transplantation (FMT) to treat ulcerative colitis. A) Diagram of 
the treatment regimens. Patient 1 received 30 rounds of FMT, Patient 2 received 25, and Patient 
3 received 22. All patients were in remission (gray shaded box) while receiving the FMT course 
and remained in remission for more than 11 weeks following their last FMT. However, all three 
eventually experienced a relapse requiring immunotherapy. Mesalamine, given orally or through a 
rectal enema, was allowed during the trial, depending on clinical disease activity. Three samples 
(indicated as triangles) were taken from each patient: one before the beginning of the FMT 
course (pre), the second after the 13th FMT (during), the third two to three weeks after finishing 
the FMT course (post). B) Bacterial lineages in the samples studied. Bacterial taxonomic 
representation and abundance was characterized by sequencing of 16S rRNA gene tags. Details 
are described in (15). C) Viral families detected in the samples studied, assessed by alignment of 
reads to a curated database of viral sequences from (18). D) Gene types inferred from analysis of 
the VLP contigs. VLP contigs were analyzed for open reading frames (ORFs), then ORFs 
annotated using CDD. Output was interpreted using custom annotation relating pfam domains to 
viral gene functions. Gene types identified are summarized to the right of the figure. Percentage 
of classified phage ORFs was 8.9%, 7.1%, 3.8% and 9.5% respectively. 
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Figure 6.2. Transfer of phage between human individuals. Transmission is shown using 
Sankey diagrams. The patients 1-3 are shown from top to bottom. For each subject, contigs 
>3000 bp are shown as the box at the left, with recipient contigs on top and donor contigs below. 
In the middle, contigs detected at the during FMT time point are shown, to the right are contigs 
detected after cessation of FMT (post). Curves with darker colors show persistence of donor 
contigs, curves with lighter colors persistence of recipient contigs. The color of each strand 
represents a single viral family. Numbers indicate the number of donor contigs transferred from 
each viral family. 
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Figure 6.3. Analysis of repeatedly transferred VLP contigs by qPCR. VLP contigs built from 
donor samples that are indicated by sequence data to be present in patients after FMT treatment, 
but not in recipient pre-FMT samples, were quantified by qPCR. VLP DNA from stool was tested 
without use of Genomifi Amplification (to reduce distortions of abundance). Abundance was 
quantified from 4 samples from the donor (two whole stool and two purified product prepared for 
FMT), the 3 recipient patients at three time points each, and 3 control individuals. As a negative 
control, Lambda DNA was also tested (far right). The dashed line along the baseline indicates the 
inferred background level in the lambda DNA negative control. Contig length, circularity, and viral 
lineage as attributed by ORF annotation is indicated on each panel. A) Contig 100-182 
(unattributed); B) Circular Contig 100-94 (Microviridae); C) Contig 100-21 (Podoviridae); D) 
Contig 19 (Myoviridae). 
 
Figure 6.4. Preferential transfer of Siphoviridae between human individuals. A) Top 
differentially transferred genes based on CDD annotation in the pfam database. A total of 302 
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CDD hits were found in the contigs. The top two domains (p-value < 0.05, odds ratio > 4) based 
on CDD annotation which were most frequently transferred are shown. B)  Comparison of the 
frequency of transfer to least 2 of the 3 patients for Siphoviridae contigs versus all others contigs 
>3000 bp. Here transfer is defined as achieving >50% coverage and >5 paired reads, where both 
reads in each pair detect the same contig. If transfer is defined as detection of a donor contig 
during FMT, post-FMT, or both in at least one patient, the favoring of Siphoviridae achieves 
p<0.0001. C) Comparison of the frequency of transfer to least 2 of the 3 patients for Siphoviridae 
contigs versus all other contigs built. D-G) Contigs annotating as Siphoviridae found in the donors 
and suggested by sequence data to be transferred to multiple recipients validated using qPCR. 
Samples tested and annotation were the same as in Figure 3. D) Contig 100-72; E) Contig 100-
230; F) Contig 100-176; G) Contig 66. 
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Supplemental Information 
Supplemental Methods 
Classifying viral read  
All MiSeq reads were BLAST aligned to a custom database (Norman et al., 2015) using an e-
value 10-3 and max_target_seqs 100. All default settings were used unless otherwise stated. The 
BLAST outputs (compressed BLAST XML format) were analyzed using MEGAN (Huson et al., 
2011) with the following parameters: minsupport=1, minscore=30.0, toppercent=10.0, and 
mincomplexity=0.44. All classifications that did not include a viral family (e.g. “root;Viruses;dsDNA 
 136 
viruses, no RNA stage; unclassified dsDNA phages”, “root;Viruses;unclassified 
phages;Enterococcus phage EF62phi”) were considered Unclassified. Proportions of the 
classified viral families were calculated. Samples with less than 50,000 reads (i.e. two negative 
control SM buffer samples) were excluded.  
Bacterial data 
Previously published bacterial 16S data (Kellermayer et al., 2015) was reanalyzed using 
R packages qiimer and vegan. Shannon diversity was calculated for each sample. A principal 
coordinate ordination plot, based on the Weighted Unifrac distances, was built. The Weighted 
Unifrac distance between each patient sample and the centroid of the donor samples was 
calculated.  
Assembling, annotating, and visualizing viral contigs 
Sequence reads were first assembled into contigs using IDBA-UD (Peng et al., 2012) 
with pre-correction and minimum and maximum k-mer lengths set to default 20 and 100 bp 
respectively. Minimo (Treangen et al., 2011), a program which utilizes a conservative overlap-
layout-consensus algorithm, was used to further combine the contigs. Contigs were built from 1) 
all 4 donor samples, including two crude stool samples and two processed samples which were 
blended and filtered to generate the liquid preparation used for the FMTs, 2) patient 1 pre-FMT’s 
samples, 3), patient 2 pre-FMT samples, and 4) patient 3 pre-FMT samples. Each of the three 
patients’ pre-FMT sample (after Genomiphi amplification) was sequenced thrice. The sequencing 
data from each patient’s pre-FMT samples was combined.  
After the contigs were built, reads from each donor and patient sample were aligned 
using Bowtie2 (Langmead and Salzberg, 2012) to each of the four sets of contigs. Bowtie’s very-
sensitive parameters (i.e. -D 20 -R 3 -N 0 -L 20 -i S,1,0.50) were used. Samtools and bedtools (Li 
et al., 2009; Quinlan and Hall, 2010) were used to parse the alignment results and assess 
genome coverage. 
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In addition to the number of reads matching each of the four sets of viral contigs, length 
of the viral contig was determined. The circularity of each contig was also assessed by looking for 
at least 10 and at most 1000 bp of overlap between the end and beginning of the contig 
sequences that were greater than 3500 bp in length.  
Entire contig sequences were then compared using BLAST with an e-value threshold 10-5 
to NCBI reference viral database, nucleotide (NT) database, and bacterial genomes database 
(downloaded January 7, 2015 from NCBI Refseq). Top matches were recorded. Additional “host” 
information was given to each contig using the following rules: 1) if a match to a reference viral 
database was found, the top match was used, 2) if no match to the viral database was found but 
a match to a bacterial genome was found, the match to the bacterial genome was used, and 3) if 
no match to the viral or bacterial reference genomes was found but a match was found to the NT 
database, that match was used.  
Contigs were then annotated with open reading frames (ORFs) using Glimmer (Salzberg 
et al., 1998), a program that utilizes the Interpolated Context Model to predict genes. Minimum 
gene length was set to 100 bp. The number of predicted ORFs was recorded. Predicted ORFs, in 
protein form, were BLAST aligned to ORFs of known viral families. The number of ORFs 
matching predicted ORFs from reference viral family sequences was recorded. A putative viral 
family was given to each contig based on the viral family with the most ORF matches. For 
example, if a contig had 4 predicted ORFs, 3 of which matched ORFs in known Siphoviridae 
viruses and 1 of which matched an ORF in a known Podoviridae virus, the contig would be 
putatively annotated as belonging to the Siphoviridae family. If only 1 of the 4 predicted ORFs 
matched an ORF in a known Siphoviridae virus and the remaining 3 ORFs did not have any 
matches, the contig would be assigned to the Siphoviridae family. In the rare instance were an 
equal number of ORFs matched two families (e.g. 2 ORFs matched one viral family and another 
2 ORFs matched another family), a viral family was selected at random.  
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Seven contigs contained ORFs that showed a top blast hit to an animal cell virus ORF. In 
all cases, the matched ORFs were a minority of all ORFs on the contig. In 5 out of 7 cases, the 
contig as a whole found a better alignment to a phage or bacterial sequence. In the remaining 2 
cases, no better matches were found but because the animal cell viruses matched 1 out of 3 or 1 
out of 6 contig ORFs, we concluded that these contigs were likely derived from phage or bacteria 
as well.  
In addition to using ORFs for providing putative viral family names, ORFs were aligned to 
conserved domains of integrase proteins with Pfam (Sonnhammer et al., 1998), the Virulence 
Factor Database (Chen et al., 2012), and Aclame database of mobile genetic elements (Leplae et 
al., 2010). The number of matches to each of these databases was recorded.  
Predicted ORFs, in protein form, were also compared to the Pfam (Sonnhammer et al., 
1998) database of conserved domains with Reversed Position Specific BLAST (RPS-
BLAST). Low compositional complexity regions were not masked and default e-value of 0.01 was 
used for the search. Pfam families were grouped using custom database with Pfam domain 
identifiers linked to phage regulation function (Minot et al., 2011). Contigs from 1) 4 donor 
samples, 2) patient 1 pre-FMT, 3) patient 2 pre-FMT, and 4) patient 3 pre-FMT were annotated 
with phage gene types.  
 Last, the number of reads from each sample mapping to each contigs were plotted. The 
size of the circle was set to represent percent of the contig covered by reads from that sample. 
The colors of each sample were used to distinguish the donor, each patient, and the control 
samples. Contig names were annotated with length and putative viral family (if any). 
Donor contigs in patients during and post-FMT 
Contig transfer was assessed separately for each patient and and then for all patients 
combined.  Transfer meant 1) an increase in the number of reads matching a contig in a patient’s 
during FMT and/or post-FMT sample(s) from the patient’s pre-FMT sample, 2) at least 5 paired 
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reads matching the contig during and/or post-FMT and 3) at least 50% coverage of the contig 
during and/or post-FMT. The number of viral contigs that transferred (as well as the contigs’ 
putative viral family name) was recorded for each patient. Viral contigs, built from the donor 
samples, could have been seen in a patient’s during FMT sample, patient’s post-FMT sample or 
both. The number of transfers as well as putative viral family classification was represented using 
Sankey plots (using R riverplot package). Contigs that were seen to be transferred in at least 2 of 
the 3 patients were also recorded. 2x2 contingency tables were built for each viral family and 
transfer, as well as pfams and transfer. Fisher’s exact test, and odds ratio, was used to calculate 
significance. 
Verification of donor contigs 
To verify our sequence results, four contigs were selected for verification with qPCR. 
Prior to qPCR, the sequence data from all of the samples was re-aligned to each contig and 
visualized using IGV (Robinson et al., 2011). Manual visual inspection confirmed the contig 
transfer plots, and qPCR assays were developed. After seeing an overrepresentation of 
Siphoviridae being transferred, 4 contigs specifically annotating as Siphoviridae were assessed 
for qPCR. Alignment of all sample reads to these contigs was again visualized in IGV and 
manually confirmed to match the contig transfer plots.  
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CHAPTER 7: Conclusion 
This dissertation describes changes in the microbial communities associated with 
disease states, how the microbial communities can be modulated to ameliorate certain disease 
states, and the possible obstacles of such modulation. Like the microbiome field, in this thesis, we 
shift from characterizing and associating microorganisms with disease states to investigating the 
possibilities of engineering communities of microorganisms to alleviate diseases. Microbiota 
transplantation has been shown to be highly efficacious in treating C. difficile infections, but much 
more work is in progress investigating its uses for other disease. We answer fundamental 
questions about the long-term durability of transplants in mice and how they are affected by diet. 
We investigate the use of microbiota transplants in the treatment of hyperammonemia. We also 
investigate the behavior of viruses during transplantations to assess a potential obstacle. This 
work serves as an important contribution to the field, particularly as we are just beginning to 
harness the power of the microbiome to cure disease. 
I begin my dissertation by characterizing the microbial community in two contexts. In 
Chapter 2, targeted sequencing was used to characterize the bacterial, archaeal, and fungal 
communities in pediatric Inflammatory Bowel Disease (IBD) patients. Similar to previous studies 
(1-5), decreased bacterial diversity was observed in pediatric IBD patients. Fungal diversity was 
reported to have decreased in IBD patients compared to healthy controls, and one Candida 
member, associated with at least five names, including Pichia jadinii, Candida utilis, 
Cyberlindnera jadinii, Torulopsis utilis, and Torula utilis (6), was found to be enriched in IBD 
patients. Only three pediatric IBD patients had detectable archaea in their stool, and all archaeal 
sequences were members of the Methanobrevibacter genus. A random forest classifier was used 
to partition pediatric samples by disease status. The greatest accuracy of the classifier, 93 
percent, could be achieved when the abundance of both bacterial and fungal community 
members was taken into account. This chapter illustrates the importance of investigating fungal 
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community members in conjunction with bacterial members, and presents clear evidence that 
fungal dysbiosis is present in pediatric IBD. 
An important question arising from this study is whether this fungal signature, or a 
combination of fungal and bacterial signatures, is useful as a molecular diagnostic tool. To 
explore this further, one must first verify that the signatures found in this paper can be 
reproduced. Recent studies have found the same Candida organism, also known as Pichia 
jadinii, to be in more abundant in IBD patients both via tagged-sequencing and metagenomics 
sequencing (7, 8). It is also important to assess whether the fungal signatures observed in 
Chapter 2 correlate with parameters such as disease severity, medication success, IBD subtype 
etc. This would allow us to determine whether fungal blooms are a response to certain IBD 
treatments or if the fungal community membership can help us distinguish between IBD subtypes. 
The few Ulcerative Colitis (UC) patients in our study did not allow us to discriminate between the 
UC and Crohn’s Disease (CD) phenotype. The number of subjects in the UC subtype would need 
to be expanded significantly to better assess differences. If studies continue to support fungal 
signatures clearly distinguishing between IBD and healthy patients, correlations between the 
fungal signatures and variables such as age, antibiotic usage, medication, immune cells, need to 
be performed. This would set the groundwork for follow-up, mechanistic studies that can link fungi 
and inflammation within our gastrointestinal tract and help answer questions concerning the role 
of specific yeast lineages in the etiology of IBD. 
Chapter 3 discusses the characterization of DNA virus in lung-transplant recipients. A 
highly abundant and diverse set of anelloviruses was found in the lungs of lung-transplant 
recipients. The anelloviruses were verified with Q-PCR and found to be 56-fold more abundant in 
lung transplant recipients compared with healthy controls or HIV+ subjects. Novel anelloviruses 
were built from the metagenomics data and phylogenetically compared to previously known 
anelloviruses. This revealed a vast diversity of anelloviruses, even within single individuals.  
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The primary follow-up to this work is to perform long-term longitudinal studies to 
determine whether levels of anelloviruses in the lung allograft are associated with, and possibly 
play a role in, transplant outcomes. Can we use abundance levels of anelloviruses or anellovirus 
diversity to track and predict lung transplant failures? Is this possible with other organ 
transplants? A study preceding ours found anelloviruses in serum following organ transplantation 
(9). They reported that anellovirus genome levels correlated with the extent of 
immunosuppression, suggesting that anellovirus DNA in blood might serve as an assay for the 
overall level of immunosuppression. This leads us to ask about the correlation between 
anellovirus levels in serum and lung allograft. Are there differences in anelloviruses species in 
different body sites within the same person? In addition to looking at anelloviruses, we must 
investigate other viruses that may be useful as indicators of immunosuppression. Our current 
tools for identifying viruses are biased towards DNA viruses and viruses that amplify well with 
Genomiphi. We need to identify others viruses known to be ubiquitous in humans and assess via 
targeted Q-PCR how their abundance levels track with immunosuppression. Viral markers can 
provide a new wave of clinical immune-monitoring strategies for organ transplant recipients. 
In Chapters 4 and 5, we replaced the entire gut microbial community of mice with a 
defined consortium of eight bacteria containing minimal urease gene content, known as Altered 
Schaedler Flora (ASF). This engineered gut microbiota was able to engraft long-term and reduce 
fecal urease activity and ammonia production, leading to decreased morbidity and mortality in a 
murine model of hepatic injury. Since the gut microbiota responds differently to environmental 
stressors such as diet, we further investigated the effects of dietary protein restriction on the 
structure and function the microbiota community engineered by inoculation with ASF. We found 
that community membership after the initial ASF inoculation was similar between mice on a 
normal protein diet (NPD) and a low protein diet (LPD), but the outgrowth of gut microbiota 
differed over the ensuing month. Nevertheless, fecal ammonia levels remained significantly lower 
in ASF-transplanted mice on a LPD compared to mice transplanted with conventional microbiota 
on a LPD, showing that the functionality of the engineered gut microbiota remained intact. These 
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findings provide insight into engineering a gut microbiota with a defined bacterial consortium, and, 
how this is affected by diet.  
It is widely known that diet is one of many factors that affect our gut microbiota. Although, 
we specifically investigated the effect of a LPD versus NPD on the engraftment of an engineered 
community, further studies investigating other perturbations are warranted. For example, how 
resilient is the engineered community if a new dose of antibiotics is given without an additional 
ASF gavage or if a conventional mouse is added to the cage of mice with established engineered 
communities? How different are the effects of the perturbations as we get farther away from the 
time of the initial ASF inoculation? How does the engraftment change in mice of different genetic 
backgrounds? Investigating these questions in the controlled-setting of animal models will help us 
predict the dynamics of defined communities in humans.  
In Chapter 6, we investigated whether viruses also transfer when microbial communities 
are transferred from one human to another. Since fecal microbiota transplantation (FMT) is a 
highly successful treatment for relapsing Clostridium difficile infection and, potentially, other 
gastrointestinal diseases, we set out to investigate the transfer of viral communities during FMT in 
pediatric UC patients. We documented transfer of multiple viral lineages between humans; none 
of which were viruses that replicated on animal cells or are known to be pathogenic. We found 
that temperate bacteriophage, which form stable associations with their hosts, were significantly 
more likely to be transferred during FMT. We conclude that our findings support a model in which 
the viral temperate replication style may have evolved in part to support efficient viral 
transmission between environments. 
The most important follow-up to the work presented in chapter 6 is to develop better tools 
to investigate the virome. Most of the viruses we find are novel viruses that cannot be annotated 
with taxonomic information. Furthermore, we need to improve the methods by which we can 
match viruses with their bacterial hosts. Our current methods include correlating abundance 
profile or using genetic homology, CRISPRs, or oligonucleotide profiles (reviewed in (10)). A 
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recent paper challenged 74 genetically defined Propionibacterium strains with 15 fully-sequenced 
phages to assess phage infection capabilities (11). We should be able to use sequence data 
coupled with these types of wet-lab results to build models to predict infectivity of bacteriophage 
and bacterial host pairs. With enough data (particularly with experiments investigating how single 
polymorphisms can alter infectivity), we should be able to take viral sequences and assign each 
nucleotide an importance score. This would allow us to take the data presented in Chapter 6 and 
predict whether viruses in a donor’s stool would survive in a recipient’s, as well as use these tools 
to investigate viral-bacterial relationships in a wide range of applications. 
This dissertation examines a broad range of questions relating to the human microbiome. 
I first discuss characterization of fungal, archaeal, and bacterial communities in pediatric IBD 
patients and viral communities in lung-transplant recipients. To better understand the dynamics 
between different bacteria, I describe studies investigating defined microbial communities in 
animal models and end with a study investigating viral communities during FMT in humans. This 
entire work took advantage of the capabilities of high-throughput sequencing, which enabled an 
unprecedented, large-scale investigation of microbial communities. The methods developed and 
discussed in this dissertation will allow other scientists to investigate the bacterial, archaeal, 
fungal, and viral communities under a different set of circumstances. The research presented 
here is meant to serve as a foundation for subsequent studies investigating the dynamic 
microorganisms that live within us. 
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